# **Annual Shareholder Report**

December 31, 2020



Share Class

Primary

Service

# Federated Hermes Kaufmann Fund II

(formerly, Federated Kaufmann Fund II)

A Portfolio of Federated Hermes Insurance Series (formerly, Federated Insurance Series)

Dear Valued Shareholder,

I am pleased to present the Annual Shareholder Report for your fund covering the period from January 1, 2020 through December 31, 2020.

While Covid-19 continues to present challenges to our lives, families and businesses, I want you to know that Federated Hermes remains dedicated to helping you successfully navigate the markets ahead. You can count on us for the insights, investment management knowledge and client service that you have come to expect. Please refer to our website, <a href="FederatedInvestors.com">FederatedInvestors.com</a>, for timely updates on this and other economic and market matters.

Thank you for investing with us. I hope you find this information useful and look forward to keeping you informed. Sincerely,

John B. Fisher, President

### CONTENTS

Management's Discussion of Fund Performance	1
Portfolio of Investments Summary Table	3
Portfolio of Investments	4
Financial Highlights	10
Statement of Assets and Liabilities	12
Statement of Operations	13
Statement of Changes in Net Assets	14
Notes to Financial Statements	15
Shareholder Expense Example	23
Board of Trustees and Trust Officers	24
Evaluation and Approval of Advisory Contract	28
Liquidity Risk Management Program – Annual Evaluation of Adequacy and Effectiveness	33
Voting Proxies on Fund Portfolio Securities	34
Quarterly Portfolio Schedule	34

# Management's Discussion of Fund Performance (unaudited)

The total return of Federated Hermes Kaufmann Fund II (the "Fund"), based on net asset value for the 12-month reporting period ended December 31, 2020, was 28.79% for the Primary Shares and 28.48% for the Service Shares. The Fund's benchmark, the Russell Midcap® Growth Index (the RMCGI), a broad-based securities market index, had a total return of 35.59% for the period. The total return of the Morningstar Insurance Mid-Cap Growth Funds Average (MIMCGFA),<sup>2</sup> the peer group average for the Fund, was 39.26%. The Fund's and MIMCGFA's total returns for the most recently completed fiscal year reflected actual cash flows, transaction costs and other expenses, which were not reflected in the total return of the RMCGI.

During the reporting period, the Fund's investment strategy focused on stock selection, sector exposure and country allocation. These were the most significant factors affecting the Fund's performance relative to the RMCGI.

The following discussion will focus on the Fund's Primary Shares relative to the RMCGI.

### MARKET OVERVIEW

During the reporting period of 2020, the U.S. and global economy both had drastic turmoil due to a pandemic impacting nearly every major economy in the world. This caused equity markets to plummet as well as economic data to suffer dramatically. However, after simultaneous fiscal and monetary posturing by nearly all governments around the world, the economy began to recover. The recovery from employment, to business confidence, to leading indicators continued through year end. Despite the historic sell-off, markets recovered and were propelled, by the end of the year, to record levels across many different exchanges.

The U.S. equity markets were positive for the reporting period with the S&P 500<sup>®</sup> Index<sup>3</sup> returning 18.40%. Large-cap stocks represented by the Russell 1000<sup>®</sup> Index<sup>4</sup> returned 20.95%, while small cap stock represented by the Russell 2000<sup>®</sup> Index<sup>5</sup> returned 19.93%. Mid-cap stocks represented by the Russell Midcap<sup>®</sup> Index<sup>6</sup> returned 30.59%. Mid-cap growth stocks outperformed mid-cap value stocks, a continuation of a multi-year trend.

The best-performing RMCGI sectors were: Communication Services (up 58.48%), Information Technology (up 47.47%) and Health Care (up 42.65%). The weakest-performing sectors during the reporting period were Energy (down 20.1%), Utilities (up 13.22%) and Consumer Staples (up 14.42%).

### STOCK SELECTION

The five stocks that contributed the most to the Fund's performance versus the RMCGI were: Ultragenyx Pharmaceutical Inc., Shopify Inc., Moderna Inc., Argenx SE and Veeva Systems.

The five stocks that most negatively affected Fund performance were: Air Lease Corp, UniQure N.V., Azul S.A., Galapagos NV and Luckin Coffee.

### SECTOR EXPOSURE

At the end of the reporting period, approximately 73% of the portfolio was invested in four large sectors: Health Care, Information Technology, Materials and Industrials. These sectors have historically provided good opportunities for bottom-up growth investors. During the reporting period, stock selection in Health Care and Energy had a positive impact on performance. The Fund maintained higher-than-benchmark exposure to cash which hurt Fund performance. The cash position of the Fund was approximately 16% on average throughout the reporting period.

### **COUNTRY ALLOCATION**

The reporting period ended with approximately 10% of the Fund invested in foreign holdings. During the reporting period, stock selection in foreign companies was a positive contributor to Fund performance. However, the allocation outside the U.S. hurt Fund performance relative to the RMCGI.


- 1 Please see the footnotes to the line graphs below for definitions of, and further information about, the RMCGI.
- 2 Please see the footnotes to the line graphs below for definitions of, and further information about, the MIMCGFA.
- 3 The S&P 500® Index is a capitalization-weighted index of 500 stocks designed to measure performance of the broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries.\*
- 4 The Russell 1000® Index measures the performance of the small-cap segment of the U.S. equity universe. It includes approximately 1000 of the smallest securities based on a combination of their market cap and current index membership.\*
- 5 The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity universe. It includes approximately 2000 of the smallest securities based on a combination of their market cap and current index membership.\*
- 6 The Russell Midcap® Index measures the performance of the mid-cap segment of the U.S. equity universe. The Russell Midcap® Index is a subset of the Russell 1000® Index. It includes approximately 800 of the smallest securities based on a combination of their market cap and current index membership.\*
- 7 International investing involves special risks including currency risk, increased volatility, political risks and differences in auditing and other
- The index is unmanaged, and it is not possible to invest directly in an index.

### **FUND PERFORMANCE AND GROWTH OF A \$10,000 INVESTMENT**

The graph below illustrates the hypothetical investment of \$10,000<sup>1</sup> in the Federated Hermes Kaufmann Fund II from December 31, 2010 to December 31, 2020, compared to the Russell Midcap<sup>®</sup> Growth Index (RMCGI)<sup>2</sup> and the Morningstar Insurance Mid-Cap Growth Funds Average (MIMCGFA).<sup>3</sup> The Average Annual Total Return table below shows returns for each class averaged over the stated periods.

### **GROWTH OF A \$10,000 INVESTMENT**

### Growth of \$10,000 as of December 31, 2020



The Fund offers multiple share classes whose performance may be greater or less than its other share class(es) due to differences in sales charges and expenses.

### Average Annual Total Returns for the Period Ended 12/31/2020

	1 Year	5 Years	10 Years
Primary Shares	28.79%	18.95%	14.75%
Service Shares	28.48%	18.65%	14.47%
RMCGI	35.59%	18.66%	15.04%
MIMCGFA	39.26%	17.80%	13.83%

Performance data quoted represents past performance which is no guarantee of future results. Investment return and principal value will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Performance of a variable investment option changes over time and current performance may be lower or higher than what is stated. For current to the most recent month-end performance, contact your insurance company. The performance information presented does not include the charges and expenses imposed by the insurance company under the variable insurance product contract. The inclusion of such charges would lower performance. Please refer to the variable insurance product prospectus for a complete listing of these expenses. Fund shares are available exclusively as a funding vehicle for life insurance companies writing variable life insurance policies and variable annuity contracts. Variable investment options are not obligations of or guaranteed by any bank and are not federally insured.

- 1 The Fund's performance assumes the reinvestment of all dividends and distributions. The RMCGI and MIMCGFA have been adjusted to reflect reinvestment of dividends on securities in the index and average.
- 2 The RMCGI measures the performance of the mid-cap growth segment of the U.S. equity universe. It includes those Russell Midcap® Index companies with higher price-to-book ratios and higher forecasted growth values. The RMCGI is constructed to provide a comprehensive and unbiased barometer of the mid-cap growth market. The RMCGI is completely reconstituted annually to ensure larger stocks do not distort the performance and characteristics of the true mid-cap growth market. The RMCGI is not adjusted to reflect sales charges, expenses or other fees that the Securities and Exchange Commission requires to be reflected in the Fund's performance. The index is unmanaged and unlike the Fund, is not affected by cash flows. It is not possible to invest directly in an index.
- 3 Morningstar figures represent the average of the total returns reported by all the funds designated by Morningstar as falling into the respective category indicated. They do not reflect sales charges. The Morningstar figures in the Growth of \$10,000 line graph are based on historical return information published by Morningstar and reflect the return of the funds comprising the category in the year of publication. Because the funds designated by Morningstar as falling into the category can change over time, the Morningstar figures in the line graph may not match the Morningstar figures in the Average Annual Total Returns table, which reflect the return of the funds that currently comprise the category.

# Portfolio of Investments Summary Table (unaudited)

At December 31, 2020, the Fund's sector composition was as follows:

Sector Composition	Percentage of Total Net Assets
Health Care	34.2%
Information Technology	19.6%
Materials	9.9%
Industrials	9.4%
Consumer Discretionary	7.0%
Financials	4.9%
Energy	1.5%
Real Estate	1.3%
Communication Services	0.9%
Consumer Staples	0.4%
Securities Lending Collateral <sup>2</sup>	2.7%
Cash Equivalents <sup>3</sup>	11.1%
Other Assets and Liabilities—Net <sup>4</sup>	(2.9)%
TOTAL	100%

<sup>1</sup> Except for Securities Lending Collateral, Cash Equivalents and Other Assets and Liabilities, sector classifications are based upon, and individual portfolio securities are assigned to, the classifications of the Global Industry Classification Standard (GICS), except that the Adviser assigns a classification to securities not classified by the GICS and to securities for which the Adviser does not have access to the classification made by the GICS.

Represents cash collateral received for portfolio securities on loan that may be invested in affiliated money market funds, other money market instruments and/or repurchase agreements.

Cash Equivalents include any investments in money market mutual funds and/or overnight repurchase agreements other than those representing securities lending collateral.

Assets, other than investments in securities, less liabilities. See Statement of Assets and Liabilities.

# Portfolio of Investments

December 31, 2020

Shares	or
Princip	al
A	

Amount		Value
	COMMON STOCKS—88.8%	
	Communication Services—0.9%	
2,756	Activision Blizzard, Inc.	\$ 255,89
38,462	<sup>1</sup> ZoomInfo Technologies, Inc.	1,855,02
,	TOTAL	2,110,91
	Consumer Discretionary—7.0%	
550	<sup>1</sup> Airbnb, Inc.	80,74
4,600	<sup>1</sup> Alibaba Group Holding Ltd., ADR	1,070,55
651	<sup>1</sup> Amazon.com, Inc.	2,120,26
1,330	<sup>1</sup> Bright Horizons Family Solutions, Inc.	230,07
5,530	<sup>1</sup> DraftKings, Inc.	250,07
3,350	<sup>1</sup> Etsy, Inc.	
26,000	1.2Fisker, Inc.	380,90
19,900	<sup>1</sup> Floor & Decor Holdings, Inc.	1,847,71
1,925	¹GrubHub, Inc.	142,97
2,100	Home Depot, Inc.	557,80
3,950	<sup>1,3</sup> Just Eat Takeaway	445,26
18,500	Las Vegas Sands Corp.	1,102,60
3,700	¹Lululemon Athletica, Inc.	1,287,71
280	<sup>1</sup> Mercadolibre, Inc.	469,06
16,700	Moncler S.p.A	1,021,47
714,400	NagaCorp Ltd.	937,04
5,165	<sup>1</sup> Planet Fitness, Inc.	400,95
825	Vail Resorts, Inc.	230,14
16,600	Wingstop, Inc.	2,200,33
15,000	<sup>1</sup> YETI Holdings, Inc.	1,027,05
	TOTAL	16,406,13
	Consumer Staples—0.4%	
500	Costco Wholesale Corp.	188,39
2,700	<sup>1</sup> Freshpet, Inc.	383,37
8,600	Grocery Outlet Holding Corp.	337,55
	TOTAL	909,31
	Energy—1.5%	•
64,441	New Fortress Energy, Inc.	3,453,39
,	Financials—4.9%	57.5575.
24,100	Apollo Global Management LLC	1,180,41
98,700	Ashmore Group PLC	582,55
2,400	BlackRock, Inc.	1,731,69
	<sup>1</sup> FinecoBank Banca Fineco SPA	2,103,60
128,900 1,400	Goldman Sachs Group, Inc.	369,19
22,200	Hamilton Lane, Inc.	1,732,71
20,200	Housing Development Finance Corp. Ltd.	709,83
33,400	KKR & Co., Inc, Class Common	1,352,36
18,015	1,3Longview Acquistion Corp.	356,51
1,000	<sup>1</sup> Markel Corp.	1,033,30
11,125	<sup>1,3</sup> Root, Inc.	174,77
	TOTAL	11,326,96
	Health Care—33.9%	
11,500	Abbott Laboratories	1,259,13
29,970	<sup>1,3</sup> Akouos, Inc.	594,30
40,300	<sup>1</sup> Albireo Pharma, Inc.	1,511,65
55,606	<sup>1</sup> Alector, Inc.	841,31
33,000	A Table 1 Tabl	
4,180	<sup>1</sup> Alnylam Pharmaceuticals, Inc.	543,27
	'Alnylam Pharmaceuticals, Inc.  1.3American Well Corp.	543,27 367,28

Amount			Value
	COMMON STOCKS—continued		
	Health Care—continued		
12,000	<sup>1</sup> Annexon, Inc.	\$	300,360
52,800	<sup>1</sup> Arcturus Therapeutics Holdings, Inc.		2,290,464
29,000	<sup>1</sup> Argenx SE		8,548,514
18,100	<sup>1</sup> Avidity Biosciences LLC		461,91
14,300	<sup>1</sup> Avrobio, Inc.		199,34
11,000	<sup>1</sup> Boston Scientific Corp.		395,45
97,600	<sup>1</sup> Calithera Biosciences, Inc.		479,21
19,800	¹Catalent, Inc.		2,060,58
137,500	¹Corcept Therapeutics, Inc.		3,597,00
	<sup>1</sup> CRISPR Therapeutics AG		1,087,08
7,100 11,700	Danaher Corp.		
			2,599,03
8,275	<sup>1</sup> Dexcom, Inc.		3,059,43
171,800	<sup>1</sup> Dynavax Technologies Corp.		764,51
26,300	<sup>1</sup> Editas Medicine, Inc.		1,843,89
7,700	<sup>1</sup> Edwards Lifesciences Corp.		702,47
3,200	<sup>1</sup> Fate Therapeutics, Inc.		290,97
20,900	<sup>1,3</sup> Frequency Therapeutics, Inc.		736,93
5,088	<sup>1</sup> Frequency Therapeutics, Inc.		179,40
2,900	<sup>1</sup> Galapagos NV		285,35
137,523	<sup>1</sup> Gamida Cell Ltd.		1,153,81
7,000	<sup>1</sup> Genmab A/S		2,831,37
16,300	<sup>1</sup> Genmab A/S, ADR		662,75
12,200	<sup>1</sup> Gossamer Bio, Inc.		117,97
12,618	<sup>1</sup> GW Pharmaceuticals PLC, ADR		1,456,24
11,275	<sup>1</sup> IDEAYA Biosciences, Inc.		157,85
1,700	<sup>1</sup> IDEXX Laboratories, Inc.		849,77
10,000	<sup>1,2</sup> Immatics N.V.		107,90
9,400	<sup>1</sup> Immatics N.V.		101,42
7,100	<sup>1</sup> Insulet Corp.		1,814,97
4,000	<sup>1</sup> Intellia Therapeutics, Inc.		217,60
715	<sup>1</sup> Intuitive Surgical, Inc.	_	584,94
13,000	<sup>1,3</sup> Kaleido Biosciences, Inc.		118,30
2,504	<sup>1</sup> Karuna Therapeutics, Inc.	_	254,38
23,600	<sup>1</sup> Legend Biotech Corp., ADR		664,57
38,400	<sup>1</sup> Merus NV		673,15
137,800	<sup>1</sup> Minerva Neurosciences, Inc.		322,45
19,400	¹Moderna, Inc.		2,026,71
20,852	¹Molecular Partners AG		486,30
29,312	<sup>1</sup> Orchard Therapeutics PLC, ADR		126,62
55,425	Otonomy, Inc.		358,60
	<sup>1</sup> PDS Biotechnology Corp.		
9,000			19,26
6,988	<sup>1</sup> Repligen Corp.		1,339,11
17,262	<sup>1</sup> Rezolute, Inc.		206,97
29,000	<sup>1</sup> Rhythm Pharmaceuticals, Inc.		862,17
3,500	<sup>1</sup> Sarepta Therapeutics, Inc.		596,71
13,770	<sup>1,3</sup> Scynexis, Inc.		105,34
58,800	<sup>1</sup> Seres Therapeutics, Inc.		1,440,60
12,087	<sup>1</sup> Stoke Therapeutics, Inc.		748,54
3,300	Stryker Corp.		808,63
23,800	<sup>1</sup> Tandem Diabetes Care, Inc.		2,277,18
29,000	<sup>1</sup> Translate Bio, Inc.		534,47
5,805	<sup>1</sup> TransMedics Group, Inc.		115,52
6,300	<sup>1</sup> Turning Point Therapeutics, Inc.		767,65
54,360	<sup>1</sup> Ultragenyx Pharmaceutical, Inc.		7,525,05
58,500	<sup>1</sup> UniQure N.V.		2,113,60
16,700	<sup>1</sup> Veeva Systems, Inc.	_	4,546,57

Amount		Value
	COMMON STOCKS—continued	
	Health Care—continued	
24,500	<sup>1</sup> Zai Lab Ltd., ADR	\$ 3,315,830
3,175	<sup>1</sup> Zentalis Pharmaceuticals, LLC	164,909
26,400	<sup>1</sup> Zogenix, Inc.	527,736
	TOTAL	78,834,542
	Industrials—9.4%	
29,705	<sup>1</sup> Azek Co., Inc.	1,142,157
30,100	<sup>1,3</sup> Azul S.A., ADR	686,882
3,530	<sup>1</sup> CoStar Group, Inc.	3,262,70
19,300	<sup>1</sup> Dun & Bradstreet Holdings, Inc.	480,570
2,750	<sup>1</sup> FTI Consulting, Inc.	307,230
7,020	Generac Holdings, Inc.	1,596,418
10,300	HEICO Corp.	1,363,720
10,000	IHS Markit Ltd.	898,300
40,038	<sup>1</sup> Mercury Systems, Inc.	3,525,74
5,200	Roper Technologies, Inc.	2,241,666
10,801	Trane Technologies PLC	1,567,873
19,096	<sup>1</sup> Trex Co., Inc.	1,598,71
6,600	United Parcel Service, Inc.	1,111,440
7,219	Verisk Analytics, Inc.	1,498,592
5,300	<sup>1</sup> XPO Logistics, Inc.	631,760
3,300	TOTAL	21,913,783
	Information Technology—19.6%	21,713,703
1,300	Adobe, Inc.	650,156
34,832	Adobe, Inc.  1Advanced Micro Devices, Inc.	3,194,443
5,300	Advanced Micro Devices, Mc.  1Ansys, Inc.	
	<sup>1</sup> Coupa Software, Inc.	1,928,140
7,616		2,581,139
2,800	<sup>1</sup> DocuSign, Inc. <sup>1</sup> Envestnet, Inc.	622,440
9,225		759,125
5,400	<sup>1</sup> Everbridge, Inc.	804,978
8,400	Fidelity National Information Services, Inc.	1,188,264
37,500	1,3GDS Holdings Ltd., ADR	3,511,500
7,580	GoDaddy, Inc.	628,76
38,500	Marvell Technology Group Ltd.	1,830,290
53,741	McAfee Corp.	896,937
15,359	<sup>1</sup> Medallia, Inc.	510,226
49,200	<sup>1</sup> Nexi SpA	977,357
50,000	<sup>1</sup> PagSeguro Digital Ltd.	2,844,000
14,300	1Q2 Holdings, Inc.	1,809,379
34,300	<sup>1</sup> Radware Ltd.	951,825
15,900	<sup>1</sup> Rapid7, Inc.	1,433,544
5,000	<sup>1</sup> RealPage, Inc.	436,200
2,900	<sup>1</sup> Salesforce.com, Inc.	645,337
7,000	<sup>1</sup> ServiceNow, Inc.	3,853,010
5,850	<sup>1</sup> Shopify, Inc.	6,621,907
10,400	<sup>1</sup> Splunk, Inc.	1,766,856
4,900	<sup>1</sup> Tyler Technologies, Inc.	2,138,948
1,661	<sup>1,3</sup> Unity Software, Inc.	254,914
11,462	<sup>1</sup> Workday, Inc.	2,746,410
	TOTAL	45,586,086
	Materials—9.9%	
46,000	Agnico Eagle Mines Ltd.	3,243,460
55,900	B2Gold Corp.	1,433,394
	Ball Corp.	1,080,888
11,600		
	Barrick Gold Corp.	1,959,080
11,600 86,000 48,200	Barrick Gold Corp. Endeavour Financial Corp.	1,959,080 1,121,599

Principal Amount		Value
	COMMON STOCKS—continued	
	Materials—continued	
150,497	Kinross Gold Corp.	\$ 1,104,648
37,544	Kirkland Lake Gold Ltd.	1,549,44
46,500	Newcrest Mining Ltd.	926,32
43,700	Newmont Corp.	2,617,193
38,510	Osisko Gold Royalties Ltd.	488,30
59,900	<sup>1</sup> Pretium Resources, Inc.	687,65
10,873	Scotts Miracle-Gro Co.	2,165,249
3,590	Sherwin-Williams Co.	2,638,32
13,500	Wheaton Precious Metals Corp.	563,49
134,485	Yamana Gold, Inc.	767,90
	TOTAL	22,936,26
	Real Estate—1.3%	
19,400	Americold Realty Trust	724,20
5,400	Crown Castle International Corp.	859,62
16,500	MGM Growth Properties LLC	516,450
7,704	Ryman Hospitality Properties	522,02
12,192	STAG Industrial, Inc.	381,85
,	TOTAL	3,004,154
	TOTAL COMMON STOCKS	-77
	(IDENTIFIED COST \$97,750,333)	206,481,557
	WARRANTS—0.3%	
	Health Care—0.3%	
11,450	<sup>1</sup> Catabasis Pharmaceuticals, Inc., Warrants, Expiration Date 2/8/2024	13,298
21,500	<sup>1</sup> Catabasis Pharmaceuticals, Inc., Warrants, Expiration Date 6/22/2022	15,628
87,500	<sup>1</sup> ContraFect Corp., Warrants, Expiration Date 7/20/2022	4,489
42,500	<sup>1</sup> ContraFect Corp., Warrants, Expiration Date 7/27/2021	26
10,000	<sup>1</sup> Dynavax Technologies Corp., Warrants, Expiration Date 2/12/2022	18,923
4,700	<sup>1</sup> Immatics N.V., Warrants, Expiration Date 12/31/2025	13,536
5,696	<sup>1</sup> Rezolute, Inc., Warrants, Expiration Date 10/8/2027	56,253
53,000	<sup>1</sup> Scynexis, Inc., Warrants, Expiration Date 1/1/2099	405,450
26,500	<sup>1</sup> Scynexis, Inc., Warrants, Expiration Date 12/21/2021	63,727
25,200	<sup>1</sup> Scynexis, Inc., Warrants, Expiration Date 3/8/2023	3,384
21,060	<sup>1</sup> Scynexis, Inc., Warrants, Expiration Date 4/6/2021	32
26,500	<sup>1</sup> Scynexis, Inc., Warrants, Expiration Date 5/21/2024	100,276
,,,,,,	TOTAL WARRANTS	
	(IDENTIFIED COST \$346,465)	695,022
	REPURCHASE AGREEMENTS—13.8%	
25,899,000	Interest in \$1,000,000,000 joint repurchase agreement 0.08%, dated 12/31/2020 under which Bank of Montreal will repurchase	
	securities provided as collateral for \$1,000,008,889 on 1/4/2021. The securities provided as collateral at the end of the period	
	held with BNY Mellon as tri-party agent, were U.S. Government Agency and U.S. Treasury securities with various maturities to 5/20/2069 and the market value of those underlying securities was \$1,022,038,963.	25,899,000
5,882,957	Interest in \$1,000,000,000 joint repurchase agreement 0.08%, dated 12/31/2020 under which Bank of Montreal will repurchase	23,077,000
3,002,737	securities provided as collateral for \$1,000,008,889 on 1/4/2021. The securities provided as collateral at the end of the period	
	held with BNY Mellon as tri-party agent, were U.S. Government Agency and U.S. Treasury securities with various maturities to	
	5/20/2069 and the market value of those underlying securities was \$1,022,038,963 (purchased with proceeds from securities	E 002 0E-
254 210	lending collateral). Interest in \$1,000,000,000 joint repurchase agreement 0.08%, dated 12/31/2020 under which Bank of Montreal will repurchase	5,882,957
354,210	securities provided as collateral for \$1,000,008,889 on 1/4/2021. The securities provided as collateral at the end of the period	
	held with BNY Mellon as tri-party agent, were U.S. Government Agency and U.S. Treasury securities with various maturities to	
	5/20/2069 and the market value of those underlying securities was \$1,022,038,963 (purchased with proceeds from securities	254.044
	lending collateral).	354,210
	TOTAL REPURCHASE AGREEMENTS (IDENTIFIED COST \$32,136,167)	22 124 14
	(IDENTIFIED COST \$32,136,167)	32,136,167
	TOTAL INVESTMENT IN SECURITIES—102.9% (IDENTIFIED COST \$130,232,965) <sup>4</sup>	239,312,746
	OTHER ASSETS AND LIABILITIES - NET—(2.9)% <sup>5</sup>	(6,749,505
	TOTAL NET ASSETS—100%	\$232,563,241

An affiliated company is a company in which the Fund, alone or in combination with other funds, has ownership of at least 5% of the voting shares. Transactions with affiliated companies during the year ended December 31, 2020, were as follows:

	alue as of 2/31/2019		urchases at Cost*		Proceeds om Sales*	U Ap	Change in Inrealized preciation/ epreciation		Net lized Gain/ (Loss)*		alue as of 2/31/2020	Shares Held as of 12/31/2020		vidend come*
Consumer Discretionary:														
Wingstop, Inc.**	\$ 1,377,093	\$	281,353	\$	(162,318)	\$	680,957	\$	23,245	\$	2,200,330	16,600	\$	91,078
Energy:														
New Fortress Energy, Inc.**	\$ 503,007	\$	917,914	\$	(217,900)	\$	2,132,004	\$	118,368	\$	3,453,393	64,441	\$	11,717
Health Care:														
Akouos, Inc.	\$ _	\$	631,160	\$	_	\$	(36,855)	\$	_	\$	594,305	29,970	\$	
Albireo Pharma, Inc.	\$ 663,462	\$	463,548	\$	_	\$	384,643	\$	_	\$	1,511,653	40,300	\$	_
Alector, Inc.	\$ 1,056,199	\$	687,587	\$	(586,505)	\$	2,562	\$	(318,524)	\$	841,319	55,606	\$	_
Amphastar Pharmaceuticals, Inc.	\$ 426,309	\$	282,695	\$	_	\$	23,000	\$	_	\$	732,004	36,400	\$	_
Arcturus Therapeutics Holdings, Inc.	\$ _	\$	3,253,857	\$	_	\$	(963,393)	\$	_	\$	2,290,464	52,800	\$	
Calithera Biosciences, Inc.	\$ 480,211	\$	72,649	\$	_	\$	(73,644)	\$	_	\$	479,216	97,600	\$	
Catabasis Pharmaceuticals, Inc., Warrants, Expiration Date 2/8/2024	\$ 35,344	\$	_	\$	_	\$	(22,046)	\$	_	\$	13,298	11,450	\$	_
Catabasis Pharmaceuticals, Inc., Warrants, Expiration Date 6/22/2022	\$ 40,489	\$	_	\$	_	\$	(24,861)	\$	_	\$	15,628	21,500	\$	
ContraFect Corp., Warrants, Expiration Date 7/20/2022	\$ 13,554	\$	_	\$	_	\$	(9,065)	\$	_	\$	4,489	87,500	\$	_
ContraFect Corp., Warrants, Expiration Date 7/27/2021	\$ 5,550	\$	_	\$	_	\$	(5,524)	\$	_	\$	26	42,500	\$	_
Corcept Therapeutics, Inc.**	\$ 2,836,240	\$	176,341	\$(	(1,368,121)	\$	969,673	\$	982,867	\$	3,597,000	137,500	\$	
Dynavax Technologies Corp.	\$ 839,696	\$	212,998	\$	(92,700)	\$	(178,124)	\$	(17,360)	\$	764,510	171,800	\$	_
Dynavax Technologies Corp., Warrants, Expiration Date 2/12/2022	\$ 32,724	\$	_	\$	_	\$	(13,801)	\$	_	\$	18,923	10,000	\$	_
Frequency Therapeutics, Inc.	\$ 366,377	\$	_	\$	_	\$	370,557	\$	_	\$	736,934	20,900	\$	
Frequency Therapeutics, Inc.	\$ _	\$	91,584	\$	_	\$	87,819	\$	_	\$	179,403	5,088	\$	
Gamida Cell Ltd.	\$ _	\$	835,445	\$	_	\$	318,373	\$	_	\$	1,153,818	137,523	\$	
Merus NV	\$ 160,512	\$	370,361	\$	_	\$	142,279	\$	_	\$	673,152	38,400	\$	_
Minerva Neurosciences, Inc.	\$ 1,458,972	\$	_	\$	(523,698)	\$	(535,299)	\$	(77,523)	\$	322,452	137,800	\$	_
Molecular Partners AG	\$ 324,040	\$	48,769	\$	(4,707)	\$	117,184	\$	1,016	\$	486,302	20,852	\$	_
Otonomy, Inc.	\$ _	\$	185,393	\$	_	\$	173,207	\$	_	\$	358,600	55,425	\$	
Rezolute, Inc.	\$ _	\$	284,810	\$	_	\$	(77,839)	\$	_	\$	206,971	17,262	\$	_
Rezolute, Inc., Warrants, Expiration Date 10/8/2027	\$ _	\$	_	\$	_	\$	56,253	\$	_	\$	56,253	5,696	\$	_
Rhythm Pharmaceuticals, Inc.	\$ 626,808	\$	35,115	\$	_	\$	200,247	\$	_	\$	862,170	29,000	\$	_
Scynexis, Inc.	\$ 126,763	\$	_	\$	(822)	\$	(6,099)	\$	(14,501)	\$	105,341	13,770	\$	
Scynexis, Inc., Warrants, Expiration Date 1/1/2099	\$ _	\$	331,197	\$	_	\$	74,253	\$	_	\$	405,450	53,000	\$	_
Scynexis, Inc., Warrants, Expiration Date 12/21/2021	\$ _	\$	_	\$	_	\$	63,727	\$	_	\$	63,727	26,500	\$	_
Scynexis, Inc., Warrants, Expiration Date 3/8/2023	\$ 7,033	\$	_	\$	_	\$	(3,649)	\$	_	\$	3,384	25,200	\$	_
Scynexis, Inc., Warrants, Expiration Date 4/6/2021	\$ 1,308	\$	_	\$	_	\$	(1,276)	\$	_	\$	32	21,060	\$	
Scynexis, Inc., Warrants, Expiration Date 5/21/2024	\$ _	\$	_	\$	_	\$	100,276	\$	_	\$	100,276	26,500	\$	_
TransMedics Group, Inc.**	\$ _	\$	338,526	\$	(239,167)	\$	34,907	\$	(18,746)	\$	115,520	5,805	\$	
Ultragenyx Pharmaceutical, Inc.	\$ 2,220,920	\$	564,469	\$	(397,289)	\$	5,121,631	\$	15,324	\$	7,525,055	54,360	\$	
UniQure N.V.	\$ 4,127,616	\$	524,861	\$	(629,056)	\$(	1,845,749)	\$	(64,067)	\$	2,113,605	58,500	\$	
Affiliated Issuers no longer in the portfolio at period end	\$ 1,064,673	\$	_	\$	(776,934)	\$	1,001,876	\$(1	,289,615)	\$	_	_	\$	
TOTAL OF AFFILIATED COMPANIES TRANSACTIONS	\$ 18,794,900	\$1	0,590,632	\$(	(4,999,217)	\$	8,258,204	\$	(659,516)	\$3	31,985,003	1,628,608	\$1	02,795

A portion of the amount shown was recorded when the Fund no longer had ownership of at least 5% of the voting shares.

<sup>\*\*</sup> At December 31, 2020, the Fund no longer has ownership of at least 5% voting shares.

- 1 Non-income-producing security.
- 2 Denotes a restricted security that either: (a) cannot be offered for public sale without first being registered, or availing of an exemption from registration, under the Securities Act of 1933; or (b) is subject to a contractual restriction on public sales. At December 31, 2020, these restricted securities amounted to \$488,800, which represented 0.2% of total net assets.
- 3 All or a portion of these securities are temporarily on loan to unaffiliated broker/dealers.
- 4 The cost of investments for federal tax purposes amounts to \$130,698,496.
- 5 Assets, other than investments in securities, less liabilities. See Statement of Assets and Liabilities.

Note: The categories of investments are shown as a percentage of total net assets at December 31, 2020.

Various inputs are used in determining the value of the Fund's investments. These inputs are summarized in the three broad levels listed below:

Level 1—quoted prices in active markets for identical securities.

Level 2—other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.). Also includes securities valued at amortized cost.

Level 3—significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments).

The inputs or methodology used for valuing securities are not an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used, as of December 31, 2020, in valuing the Fund's assets carried at fair value:

### **Valuation Inputs**

	Level 1— Quoted Prices	Level 2— Other Significant Observable Inputs	Level 3— Significant Unobservable Inputs	Total
Equity Securities:				
Common Stocks				
Domestic	\$183,482,259	\$ —	\$—	\$183,482,259
International	_	22,999,298	_	22,999,298
Debt Securities:				
Warrants	_	695,022	_	695,022
Repurchase Agreements	_	32,136,167	_	32,136,167
TOTAL SECURITIES	\$183,482,259	\$55,830,487	\$—	\$239,312,746

The following acronym(s) are used throughout this portfolio:

ADR—American Depositary Receipt

# Financial Highlights - Primary Shares

(For a Share Outstanding Throughout Each Period)

		Year Ended December 31,					
	2020	2019	2018	2017	2016		
Net Asset Value, Beginning of Period	\$22.63	\$18.55	\$19.16	\$16.70	\$17.42		
Income From Investment Operations:							
Net investment income (loss) <sup>1</sup>	(0.22)	(0.10)	(0.11)	(0.14)	(0.11)		
Net realized and unrealized gain	5.27	6.15	0.95	4.54	0.56		
TOTAL FROM INVESTMENT OPERATIONS	5.05	6.05	0.84	4.40	0.45		
Less Distributions:							
Distributions from net realized gain	(2.22)	(1.97)	(1.45)	(1.94)	(1.17)		
Net Asset Value, End of Period	\$25.46	\$22.63	\$18.55	\$19.16	\$16.70		
Total Return <sup>2</sup>	28.79%	33.82%	3.84%	28.33%	3.66%		
Ratios to Average Net Assets:							
Net expenses <sup>3</sup>	1.50%	1.51%	1.52%	1.54%	1.54%		
Net investment loss	(1.01)%	(0.49)%	(0.53)%	(0.77)%	(0.67)%		
Expense waiver/reimbursement <sup>5</sup>	<b>—</b> %	-%	-%	-%	0.03%		
Supplemental Data:							
Net assets, end of period (000 omitted)	\$63,502	\$57,988	\$46,160	\$47,985	\$42,122		
Portfolio turnover	45%	43%	41%	44%	59%		

<sup>1</sup> Per share numbers have been calculated using the average shares method.

<sup>2</sup> Based on net asset value. Total returns do not reflect any additional fees or expenses that may be imposed by separate accounts of insurance companies or in connection with any variable annuity or variable life insurance contract.

<sup>3</sup> Amount does not reflect net expenses incurred by investment companies in which the Fund may invest.

<sup>4</sup> The net expense ratio is calculated without reduction for expense offset arrangements. The net expense ratio was 1.54% for the year ended December 31, 2016, after taking into account these expense reductions.

<sup>5</sup> This expense decrease is reflected in both the net expense and the net investment income ratios shown above. Amount does not reflect expense waiver/reimbursement recorded by investment companies in which the Fund may invest.

# Financial Highlights – Service Shares

(For a Share Outstanding Throughout Each Period)

		Year Ended December 31,					
	2020	2019	2018	2017	2016		
Net Asset Value, Beginning of Period	\$21.27	\$17.57	\$18.26	\$16.04	\$16.82		
Income From Investment Operations:							
Net investment income (loss) <sup>1</sup>	(0.26)	(0.15)	(0.15)	(0.17)	(0.14)		
Net realized gain (loss)	4.86	5.82	0.91	4.33	0.53		
TOTAL FROM INVESTMENT OPERATIONS	4.60	5.67	0.76	4.16	0.39		
Less Distributions:							
Distributions from net realized gain	(2.22)	(1.97)	(1.45)	(1.94)	(1.17)		
Net Asset Value, End of Period	\$23.65	\$21.27	\$17.57	\$18.26	\$16.04		
Total Return <sup>2</sup>	28.48%	33.52%	3.58%	27.97%	3.42%		
Ratios to Average Net Assets:							
Net expenses <sup>3</sup>	1.75%	1.76%	1.77%	1.79%	1.79%4		
Net investment loss	(1.26)%	(0.74)%	(0.77)%	(1.02)%	(0.92)%		
Expense waiver/reimbursement <sup>5</sup>	_%	-%	-%	-%	0.03%		
Supplemental Data:							
Net assets, end of period (000 omitted)	\$169,061	\$129,327	\$105,132	\$96,037	\$78,870		
Portfolio turnover	45%	43%	41%	44%	59%		

<sup>1</sup> Per share numbers have been calculated using the average shares method.

<sup>2</sup> Based on net asset value. Total returns do not reflect any additional fees or expenses that may be imposed by separate accounts of insurance companies or in connection with any variable annuity or variable life insurance contract.

<sup>3</sup> Amount does not reflect net expenses incurred by investment companies in which the Fund may invest.

<sup>4</sup> The net expense ratio is calculated without reduction for expense offset arrangements. The net expense ratio was 1.79% for the year ended December 31, 2016, after taking into account these expense reductions.

<sup>5</sup> This expense decrease is reflected in both the net expense and the net investment income ratios shown above. Amount does not reflect expense waiver/reimbursement recorded by investment companies in which the Fund may invest.

# Statement of Assets and Liabilities

December 31, 2020

Δ	SS	et	·c

\$ 33	2,136,167
20	7,176,579
	9,312,746
_	436,823
_	43,733
	163,918
239	9,957,220
_	514,399
_	521,161
	6,237,167
	8,335
_	500
	36,135
	76,282
-	7,393,979
\$232	2,563,241
\$10	7,470,602
12!	5,092,639
\$232	2,563,241
_	
\$	25.46
 \$	23.65
	20 d 23

<sup>\*</sup> See information listed after the Fund's Portfolio of Investments.

# Statement of Operations

Year Ended December 31, 2020

П	Inves	+m.	n m t	· Im		100.0	
П	IIIVES	LIII	enı		LU	ше	•

investment income.	
Dividends (including \$102,795 received from affiliated holdings* and net of foreign taxes withheld of \$28,375)	\$ 849,827
Interest	97,351
Net income on securities loaned (Note 2)	45,235
TOTAL INCOME	992,413
Expenses:	
Investment adviser fee (Note 5)	2,605,273
Administrative fee (Note 5)	157,654
Custodian fees	35,775
Transfer agent fees	17,334
Directors'/Trustees' fees (Note 5)	2,038
Auditing fees	32,840
Legal fees	11,429
Portfolio accounting fees	75,764
Distribution services fee (Note 5)	356,330
Printing and postage	36,039
Miscellaneous (Note 5)	36,287
TOTAL EXPENSES	3,366,763
Net investment income (loss)	(2,374,350)
Realized and Unrealized Gain (Loss) on Investments, Foreign Currency Transactions and Futures Contracts:	
Net realized gain on investments (including net realized loss of \$(659,516) on sales of investments in affiliated companies*)	18,626,091
Net realized gain on foreign currency transactions	15,939
Net realized loss on futures contracts	(1,518,084)
Net change in unrealized appreciation of investments (including net change in unrealized appreciation of \$8,258,204 on investments in affiliated companies*)	36,971,842
Net change in unrealized appreciation/depreciation of translation of assets and liabilities in foreign currency	119
Net realized and unrealized gain (loss) on investments, foreign currency transactions and futures contracts	54,095,907
Change in net assets resulting from operations	\$51,721,557

<sup>\*</sup> See information listed after the Fund's Portfolio of Investments.

# Statement of Changes in Net Assets

Year Ended December 31	2020	2019
Increase (Decrease) in Net Assets		
Operations:		
Net investment income (loss)	\$ (2,374,350)	\$ (1,173,930)
Net realized gain (loss)	17,123,946	18,258,834
Net change in unrealized appreciation/depreciation	36,971,961	31,925,071
CHANGE IN NET ASSETS RESULTING FROM OPERATIONS	51,721,557	49,009,975
Distributions to Shareholders:		
Primary Shares	(5,382,824)	(4,810,725)
Service Shares	(12,836,300)	(11,433,059)
CHANGE IN NET ASSETS RESULTING FROM DISTRIBUTIONS TO SHAREHOLDERS	(18,219,124)	(16,243,784)
Share Transactions:		
Proceeds from sale of shares	51,579,563	39,703,166
Net asset value of shares issued to shareholders in payment of distributions declared	18,219,109	16,243,770
Cost of shares redeemed	(58,053,310)	(52,689,616)
CHANGE IN NET ASSETS RESULTING FROM SHARE TRANSACTIONS	11,745,362	3,257,320
Change in net assets	45,247,795	36,023,511
Net Assets:		
Beginning of period	187,315,446	151,291,935
End of period	\$232,563,241	\$187,315,446

### Notes to Financial Statements

December 31, 2020

### 1. ORGANIZATION

Federated Hermes Insurance Series (the "Trust") is registered under the Investment Company Act of 1940, as amended (the "Act"), as an open-end management investment company. The Trust consists of six portfolios. The financial statements included herein are only those of Federated Hermes Kaufmann Fund II (the "Fund"), a diversified portfolio. The financial statements of the other portfolios are presented separately. The assets of each portfolio are segregated and a shareholder's interest is limited to the portfolio in which shares are held. Each portfolio pays its own expenses. The Fund offers two classes of shares: Primary Shares and Service Shares. All shares of the Fund have equal rights with respect to voting, except on class-specific matters. Fund shares are available exclusively as a funding vehicle for life insurance companies writing variable life insurance policies and variable annuity contracts. The investment objective of the Fund is capital appreciation.

Prior to April 28, 2020, the names of the Trust and Fund were Federated Insurance Series and Federated Kaufmann Fund II, respectively.

### 2. SIGNIFICANT ACCOUNTING POLICIES

The following is a summary of significant accounting policies consistently followed by the Fund in the preparation of its financial statements. These policies are in conformity with U.S. generally accepted accounting principles (GAAP).

### Investment Valuation

In calculating its net asset value (NAV), the Fund generally values investments as follows:

- Equity securities listed on an exchange or traded through a regulated market system are valued at their last reported sale price or official closing price in their principal exchange or market.
- Fixed-income securities are fair valued using price evaluations provided by a pricing service approved by the Trustees.
- Shares of other mutual funds or non-exchange-traded investment companies are valued based upon their reported NAVs.
- Derivative contracts listed on exchanges are valued at their reported settlement or closing price, except that options are valued at the
  mean of closing bid and asked quotations.
- Over-the-counter (OTC) derivative contracts are fair valued using price evaluations provided by a pricing service approved by the Trustees.
- For securities that are fair valued in accordance with procedures established by and under the general supervision of the Trustees, certain factors may be considered, such as: the last traded or purchase price of the security, information obtained by contacting the issuer or dealers, analysis of the issuer's financial statements or other available documents, fundamental analytical data, the nature and duration of restrictions on disposition, the movement of the market in which the security is normally traded, public trading in similar securities or derivative contracts of the issuer or comparable issuers, movement of a relevant index, or other factors including but not limited to industry changes and relevant government actions.

If any price, quotation, price evaluation or other pricing source is not readily available when the NAV is calculated, if the Fund cannot obtain price evaluations from a pricing service or from more than one dealer for an investment within a reasonable period of time as set forth in the Fund's valuation policies and procedures, or if information furnished by a pricing service, in the opinion of the valuation committee ("Valuation Committee"), is deemed not representative of the fair value of such security, the Fund uses the fair value of the investment determined in accordance with the procedures described below. There can be no assurance that the Fund could obtain the fair value assigned to an investment if it sold the investment at approximately the time at which the Fund determines its NAV per share, and the actual value obtained could be materially different.

### Fair Valuation and Significant Events Procedures

The Trustees have ultimate responsibility for determining the fair value of investments for which market quotations are not readily available. The Trustees have appointed a Valuation Committee comprised of officers of the Fund, Federated Equity Management Company of Pennsylvania (the "Adviser") and certain of the Adviser's affiliated companies to assist in determining fair value and in overseeing the calculation of the NAV. The Trustees have also authorized the use of pricing services recommended by the Valuation Committee to provide fair value evaluations of the current value of certain investments for purposes of calculating the NAV. The Valuation Committee employs various methods for reviewing third-party pricing-service evaluations including periodic reviews of third-party pricing services' policies, procedures and valuation methods (including key inputs, methods, models and assumptions), transactional back-testing, comparisons of evaluations of different pricing services, and review of price challenges by the Adviser based on recent market activity. In the event that market quotations and price evaluations are not available for an investment, the Valuation Committee determines the fair value of the investment in accordance with procedures adopted by the Trustees. The Trustees periodically review and approve the fair valuations made by the Valuation Committee and any changes made to the procedures.

Factors considered by pricing services in evaluating an investment include the yields or prices of investments of comparable quality, coupon, maturity, call rights and other potential prepayments, terms and type, reported transactions, indications as to values from dealers and general market conditions. Some pricing services provide a single price evaluation reflecting the bid-side of the market for an investment (a "bid" evaluation). Other pricing services offer both bid evaluations and price evaluations indicative of a price between the prices bid and asked for the investment (a "mid" evaluation). The Fund normally uses bid evaluations for any U.S. Treasury and Agency securities, mortgage-backed securities and municipal securities. The Fund normally uses mid evaluations for any other types of fixed-income securities and any OTC derivative contracts. In the event that market quotations and price evaluations are not available for an investment, the fair value of the investment is determined in accordance with procedures adopted by the Trustees.

The Trustees also have adopted procedures requiring an investment to be priced at its fair value whenever the Adviser determines that a significant event affecting the value of the investment has occurred between the time as of which the price of the investment would otherwise be determined and the time as of which the NAV is computed. An event is considered significant if there is both an affirmative expectation that the investment's value will change in response to the event and a reasonable basis for quantifying the resulting change in value. Examples of significant events that may occur after the close of the principal market on which a security is traded, or after the time of a price evaluation provided by a pricing service or a dealer, include:

- With respect to securities traded principally in foreign markets, significant trends in U.S. equity markets or in the trading of foreign securities index futures contracts;
- Political or other developments affecting the economy or markets in which an issuer conducts its operations or its securities are traded;
- Announcements concerning matters such as acquisitions, recapitalizations, litigation developments, or a natural disaster affecting the issuer's operations or regulatory changes or market developments affecting the issuer's industry.

The Trustees have adopted procedures whereby the Valuation Committee uses a pricing service to provide factors to update the fair value of equity securities traded principally in foreign markets from the time of the close of their respective foreign stock exchanges to the pricing time of the Fund. For other significant events, the Fund may seek to obtain more current quotations or price evaluations from alternative pricing sources. If a reliable alternative pricing source is not available, the Fund will determine the fair value of the investment in accordance with the fair valuation procedures approved by the Trustees. The Trustees have ultimate responsibility for any fair valuations made in response to a significant event.

### Repurchase Agreements

The Fund may invest in repurchase agreements for short-term liquidity purposes. It is the policy of the Fund to require the other party to a repurchase agreement to transfer to the Fund's custodian or sub-custodian eligible securities or cash with a market value (after transaction costs) at least equal to the repurchase price to be paid under the repurchase agreement. The eligible securities are transferred to accounts with the custodian or sub-custodian in which the Fund holds a "securities entitlement" and exercises "control" as those terms are defined in the Uniform Commercial Code. The Fund has established procedures for monitoring the market value of the transferred securities and requiring the transfer of additional eligible securities if necessary to equal at least the repurchase price. These procedures also allow the other party to require securities to be transferred from the account to the extent that their market value exceeds the repurchase price or in exchange for other eligible securities of equivalent market value.

The insolvency of the other party or other failure to repurchase the securities may delay the disposition of the underlying securities or cause the Fund to receive less than the full repurchase price. Under the terms of the repurchase agreement, any amounts received by the Fund in excess of the repurchase price and related transaction costs must be remitted to the other party.

The Fund may enter into repurchase agreements in which eligible securities are transferred into joint trading accounts maintained by the custodian or sub-custodian for investment companies and other clients advised by the Fund's Adviser and its affiliates. The Fund will participate on a pro rata basis with the other investment companies and clients in its share of the securities transferred under such repurchase agreements and in its share of proceeds from any repurchase or other disposition of such securities.

Repurchase agreements are subject to Master Netting Agreements (MNA) which are agreements between the Fund and its counterparties that provide for the net settlement of all transactions and collateral with the Fund, through a single payment, in the event of default or termination. Amounts presented on the Portfolio of Investments and Statement of Assets and Liabilities are not net settlement amounts but gross. As indicated above, the cash or securities to be repurchased, as shown on the Portfolio of Investments, exceeds the repurchase price to be paid under the agreement reducing the net settlement amount to zero.

### Investment Income, Gains and Losses, Expenses and Distributions

Investment transactions are accounted for on a trade-date basis. Realized gains and losses from investment transactions are recorded on an identified-cost basis. Interest income and expenses are accrued daily. Dividend income and distributions to shareholders are recorded on the ex-dividend date. Foreign dividends are recorded on the ex-dividend date or when the Fund is informed of the ex-dividend date. Amortization/accretion of premium and discount is included in investment income. Distributions of net investment income, if any, are declared and paid annually. Non-cash dividends included in dividend income, if any, are recorded at fair value. Investment income, realized and unrealized gains and losses, and certain fund-level expenses are allocated to each class based on relative average daily net assets, except that select classes will bear certain expenses unique to those classes.

Dividends are declared separately for each class. No class has preferential dividend rights; differences in per share dividend rates are generally due to differences in separate class expenses.

### **Federal Taxes**

It is the Fund's policy to comply with the Subchapter M provision of the Internal Revenue Code and to distribute to shareholders each year substantially all of its income. Accordingly, no provision for federal income tax is necessary. As of and during the year ended December 31, 2020, the Fund did not have a liability for any uncertain tax positions. The Fund recognizes interest and penalties, if any, related to tax liabilities as income tax expense in the Statement of Operations. As of December 31, 2020, tax years 2017 through 2020 remain subject to examination by the Fund's major tax jurisdictions, which include the United States of America and the Commonwealth of Massachusetts.

The Fund may be subject to taxes imposed by governments of countries in which it invests. Such taxes are generally based on either income or gains earned or repatriated. The Fund accrues and applies such taxes to net investment income, net realized gains and net unrealized gains as income and/or gains are earned.

### When-Issued and Delayed-Delivery Transactions

The Fund may engage in when-issued or delayed-delivery transactions. The Fund records when-issued securities on the trade date and maintains security positions such that sufficient liquid assets will be available to make payment for the securities purchased. Securities purchased on a when-issued or delayed-delivery basis are marked to market daily and begin earning interest on the settlement date. Losses may occur on these transactions due to changes in market conditions or the failure of counterparties to perform under the contract.

### **Futures Contracts**

The Fund purchases and sells financial futures contracts to manage currency risk and market risks. Upon entering into a financial futures contract with a broker, the Fund is required to deposit with a broker, either U.S. government securities or a specified amount of cash, which is shown as due from broker in the Statement of Assets and Liabilities. Futures contracts are valued daily and unrealized gains or losses are recorded in a "variation margin" account. The Fund receives from or pays to the broker a specified amount of cash based upon changes in the variation margin account. When a contract is closed, the Fund recognizes a realized gain or loss. Futures contracts have market risks, including the risk that the change in the value of the contract may not correlate with the changes in the value of the underlying securities. There is minimal counterparty risk to the Fund since futures contracts are exchange traded and the exchange's clearing house, as counterparty to all exchange traded futures contracts, guarantees the futures contracts against default.

At December 31, 2020, the fund had no outstanding Futures contracts.

The average notional value of short futures contracts held by the Fund throughout the period was \$1,290,280. This is based on amounts held as of each month-end throughout the fiscal period.

### Foreign Exchange Contracts

The Fund enters into foreign exchange contracts for the delayed-delivery of securities or foreign currency exchange transactions. The Fund enters into foreign exchange contracts to protect assets against adverse changes in foreign currency exchange rates or exchange control regulations. Purchased contracts are used to acquire exposure to foreign currencies, whereas, contracts to sell are used to hedge the Fund's securities against currency fluctuations. Risks may arise upon entering into these transactions from the potential inability of counterparties to meet the terms of their commitments and from unanticipated movements in security prices or foreign exchange rates. The foreign exchange contracts are adjusted by the daily exchange rate of the underlying currency and any gains or losses are recorded for financial statement purposes as unrealized until the settlement date.

At December 31, 2020, the Fund had no outstanding foreign exchange contracts.

### **Foreign Currency Translation**

The accounting records of the Fund are maintained in U.S. dollars. All assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the rates of exchange of such currencies against U.S. dollars on the date of valuation. Purchases and sales of securities, income and expenses are translated at the rate of exchange quoted on the respective date that such transactions are recorded. The Fund does not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. Such fluctuations are included with the net realized and unrealized gain or loss from investments.

Reported net realized foreign exchange gains or losses arise from sales of foreign currencies, currency gains or losses realized between the trade and settlement dates on securities transactions, the difference between the amounts of dividends, interest and foreign withholding taxes recorded on the Fund's books, and the U.S. dollar equivalent of the amounts actually received or paid. Net unrealized foreign exchange gains and losses arise from changes in the value of assets and liabilities other than investments in securities at period end, resulting from changes in the exchange rate.

### **Securities Lending**

The Fund participates in a securities lending program providing for the lending of equity securities to qualified brokers. The term of the loans within the program is one year or less. The Fund normally receives cash collateral for securities loaned that may be invested in affiliated money market funds, other money market instruments and/or repurchase agreements. Investments in money market funds may include funds with a "floating" NAV that can impose redemption fees and liquidity gates, impose certain operational impediments to investing cash collateral, and, if the investee fund's NAV decreases, result in the Fund recognizing losses and being required to cover the decrease in the value of the cash collateral. Collateral is maintained at a minimum level of 100% of the market value of investments loaned, plus interest, if applicable. In accordance with the Fund's securities lending agreement, the market value of securities on loan is determined each day at the close of business and any additional collateral required to cover the value of securities on loan is delivered to the Fund on the next business day. Earnings on collateral are allocated between the borrower of the security, the securities lending agent, as a fee for its services under the program and the Fund, according to agreed-upon rates. The Fund will not have the right to vote on securities while they are on loan. However, the Fund will attempt to terminate a loan in an effort to reacquire the securities in time to vote on matters that are deemed to be material by the Adviser. There can be no assurance that the Fund will have sufficient notice of such matters to be able to terminate the loan in time to vote thereon.

Securities lending transactions are subject to Master Netting Agreements which are agreements between the Fund and its counterparties that provide for the net settlement of all transactions and collateral with the Fund, through a single payment, in the event of default or termination. Amounts presented on the Portfolio of Investments and Statement of Assets and Liabilities are not net settlement amounts but gross. As indicated below, the cash collateral received by the Fund exceeds the market value of the securities loaned reducing the net settlement amount to zero. The chart below identifies the amount of collateral received as well as the market value of securities on loan. Additionally, the securities lending agreement executed by the Fund includes an indemnification clause. This clause stipulates that the borrower will reimburse the Fund for any losses as a result of any failure of the borrower to return equivalent securities to the Fund.

As of December 31, 2020, securities subject to this type of arrangement and related collateral were as follows:

Market Value of	Collateral
Securities Loaned	Received
\$6,021,858	\$6,237,167

### **Restricted Securities**

The Fund may purchase securities which are considered restricted. Restricted securities are securities that either: (a) cannot be offered for public sale without first being registered, or being able to take advantage of an exemption from registration, under the Securities Act of 1933; or (b) are subject to contractual restrictions on public sales. In some cases, when a security cannot be offered for public sale without first being registered, the issuer of the restricted security has agreed to register such securities for resale, at the issuer's expense, either upon demand by the Fund or in connection with another registered offering of the securities. Many such restricted securities may be resold in the secondary market in transactions exempt from registration. Restricted securities may be determined to be liquid under criteria established by the Trustees. The Fund will not incur any registration costs upon such resales. The Fund's restricted securities, like other securities, are priced in accordance with procedures established by and under the general supervision of the Trustees.

Additional information on restricted securities, held at December 31, 2020, is as follows:

Security	Acquisition Date	Cost	Value
Fisker, Inc.	10/29/2020	\$260,000	\$380,900
Immatics N.V.	6/30/2020	\$100,000	\$107,900

### The Effect of Derivative Instruments on the Statement of Operations for the Year Ended December 31, 2020

### Amount of Realized Gain or (Loss) on Derivatives Recognized in Income

	Futures Contracts
Equity contracts	\$(1,518,084)

### Other

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets, liabilities, expenses and revenues reported in the financial statements. Actual results could differ materially from those estimated. The Fund applies investment company accounting and reporting guidance.

### 3. SHARES OF BENEFICIAL INTEREST

The following tables summarize share activity:

Primary Shares:		Year Ended 12/31/2020		Year Ended 12/31/2019	
	Shares	Amount	Shares	Amount	
Shares sold	146,298	\$ 3,203,683	271,211	\$ 5,716,979	
Shares issued to shareholders in payment of distributions declared	350,901	5,382,822	236,865	4,810,723	
Shares redeemed	(566,093)	(12,397,252)	(434,328)	(9,130,046)	
NET CHANGE RESULTING FROM PRIMARY SHARE TRANSACTIONS	(68,894)	\$ (3,810,747)	73,748	\$ 1,397,656	

		Year Ended 12/31/2020		Year Ended 12/31/2019	
Service Shares:	Shares	Amount	Shares	Amount	
Shares sold	2,374,103	\$ 48,375,880	1,711,055	\$ 33,986,187	
Shares issued to shareholders in payment of distributions declared	898,900	12,836,287	597,650	11,433,047	
Shares redeemed	(2,205,894)	(45,656,058)	(2,211,316)	(43,559,570)	
NET CHANGE RESULTING FROM SERVICE SHARE TRANSACTIONS	1,067,109	\$ 15,556,109	97,389	\$ 1,859,664	
NET CHANGE RESULTING FROM TOTAL FUND SHARE TRANSACTIONS	998,215	\$ 11,745,362	171,137	\$ 3,257,320	

### 4. FEDERAL TAX INFORMATION

The accounting treatment of certain items in accordance with income tax regulations may differ from the accounting treatment in accordance with GAAP which may result in permanent differences. In the case of the Fund, such differences primarily result from net operating losses.

For the year ended December 31, 2020, permanent differences identified and reclassified among the components of net assets were as follows:

### Increase (Decrease)

	lotal distributable
Paid-In Capital	Earnings (Loss)
\$(1,596,082)	\$1,596,082

Total Distributable

Net assets were not affected by this reclassification.

The tax character of distributions as reported on the Statement of Changes in Net Assets for the years ended December 31, 2020 and 2019, was as follows:

	2020	2019
Long-term capital gains	\$18,219,124	\$16,243,784
As of December 31, 2020, the components of distributable earnings on a tax-basis were as follows:		
Net unrealized appreciation		\$108,614,241
Undistributed long-term capital gains		\$ 16.478.398

The difference between book-basis and tax-basis net unrealized appreciation is attributable to the differing treatments for deferral of losses on wash sales and passive foreign investment company adjustments.

At December 31, 2020, the cost of investments for federal tax purposes was \$130,698,496. The net unrealized appreciation of investments for federal tax purposes was \$108,614,250. This consists of net unrealized appreciation from investments for those securities having an excess of value over cost of \$111,323,835 and net unrealized depreciation from investments for those securities having an excess of cost over value of \$2,709,585.

### 5. INVESTMENT ADVISER FEE AND OTHER TRANSACTIONS WITH AFFILIATES

### Investment Adviser Fee

The advisory agreement between the Fund and the Adviser provides for an annual fee equal to 1.30% of the Fund's average daily net assets. Subject to the terms described in the Expense Limitation note, the Adviser may voluntarily choose to waive any portion of its fee.

Certain of the Fund's assets are managed by Federated Global Investment Management Corp. (the "Sub-Adviser"). Under the terms of a sub-advisory agreement between the Adviser and the Sub-Adviser, the Sub-Adviser receives an allocable portion of the Fund's adviser fee. The fee is paid by the Adviser out of its resources and is not an incremental Fund expense. For the year ended December 31, 2020, the Sub-Adviser earned a fee of \$2,136,324.

### Administrative Fee

Federated Administrative Services (FAS), under the Administrative Services Agreement, provides the Fund with administrative personnel and services. For purposes of determining the appropriate rate breakpoint, "Investment Complex" is defined as all of the Federated Hermes Funds subject to a fee under the Administrative Services Agreement. The fee paid to FAS is based on the average daily net assets of the Investment Complex as specified below:

Administrative Fee	Average Daily Net Assets of the Investment Complex
0.100%	on assets up to \$50 billion
0.075%	on assets over \$50 billion

FAS may voluntarily choose to waive any portion of its fee. For the year ended December 31, 2020, the annualized fee paid to FAS was 0.079% of average daily net assets of the Fund.

In addition, FAS may charge certain out-of-pocket expenses to the Fund.

### **Distribution Services Fee**

The Fund has adopted a Distribution Plan (the "Plan") pursuant to Rule 12b-1 under the Act. Under the terms of the Plan, the Fund will compensate Federated Securities Corp. (FSC), the principal distributor, from the daily net assets of the Fund's Primary Shares and Service Shares to finance activities intended to result in the sale of these shares. The Plan provides that the Fund may incur distribution expenses at the following percentages of average daily net assets annually, to compensate FSC:

	Percentage of Average Daily Net Assets of Class
Primary Shares	0.25%
Service Shares	0.25%

FSC may voluntarily choose to waive any portion of its fee. For the year ended December 31, 2020, distribution services fees for the Fund were as follows:

	Distribution Services Fees Incurred
Service Shares	\$356,330

When FSC receives fees, it may pay some or all of them to financial intermediaries whose customers purchase shares. For the year ended December 31, 2020, FSC did not retain any fees paid by the Fund. For the year ended December 31, 2020, the Fund's Primary Shares did not incur a distribution services fee; however, it may begin to incur this fee upon approval of the Trustees.

### **Interfund Transactions**

During the year ended December 31, 2020, the Fund engaged in purchase and sale transactions with funds that have a common investment adviser (or affiliated investment advisers), common Directors/Trustees and/or common Officers. These purchase and sale transactions complied with Rule 17a-7 under the Act and amounted to \$238,453 and \$4,422,604, respectively. Net realized gain recognized on these transactions was \$885,155.

### Directors'/Trustees' and Miscellaneous Fees

Certain Officers and Trustees of the Fund are Officers and Directors or Trustees of certain of the above companies. To efficiently facilitate payment, Independent Directors'/Trustees' fees and certain expenses related to conducting meetings of the Directors/Trustees and other miscellaneous expenses are paid by an affiliate of the Adviser which in due course are reimbursed by the Fund. These expenses related to conducting meetings of the Directors/Trustees and other miscellaneous expenses may be included in Accrued and Miscellaneous Expenses on the Statement of Assets and Liabilities and Statement of Operations, respectively.

### 6. INVESTMENT TRANSACTIONS

Purchases and sales of investments, excluding long-term U.S. government securities and short-term obligations, for the year ended December 31, 2020, were as follows:

Purchases	\$76,786,093
Sales	\$84,245,987

### 7. CONCENTRATION OF RISK

The Fund may invest a portion of its assets in securities of companies that are deemed by the Fund's management to be classified in similar business sectors. Economic developments may have an effect on the liquidity and volatility of the portfolio securities.

### 8. LINE OF CREDIT

The Fund participates with certain other Federated Hermes Funds, on a several basis, in an up to \$500,000,000 unsecured, 364-day, committed, revolving line of credit (LOC) agreement dated June 24, 2020. The LOC was made available to temporarily finance the repurchase or redemption of shares of the Fund, failed trades, payment of dividends, settlement of trades and for other short-term, temporary or emergency general business purposes. The Fund cannot borrow under the LOC if an inter-fund loan is outstanding. The Fund's ability to borrow under the LOC also is subject to the limitations of the Act and various conditions precedent that must be satisfied before the Fund can borrow. Loans under the LOC are charged interest at a fluctuating rate per annum equal to the highest, on any day, of (a) (i) the federal funds effective rate, (ii) the one month London Interbank Offered Rate (LIBOR), or a replacement rate as appropriate, and (iii) 0.0%, plus (b) a margin. Any fund eligible to borrow under the LOC pays its pro rata share of an upfront fee, and its pro rata share of a commitment fee based on the amount of the lenders' commitment that has not been utilized, quarterly in arrears and at maturity. As of December 31, 2020, the Fund had no outstanding loans. During the year ended December 31, 2020, the Fund did not utilize the LOC.

### 9. INTERFUND LENDING

Pursuant to an Exemptive Order issued by the Securities and Exchange Commission, the Fund, along with other funds advised by subsidiaries of Federated Hermes, Inc., may participate in an interfund lending program. This program provides an alternative credit facility allowing the Fund to borrow from other participating affiliated funds. As of December 31, 2020, there were no outstanding loans. During the year ended December 31, 2020, the program was not utilized.

### 10. OTHER MATTERS

An outbreak of respiratory disease caused by a novel coronavirus was first detected in China in late 2019 and subsequently spread globally. As of the date of the issuance of these financial statements, this coronavirus has resulted in closing borders, enhanced health screenings, healthcare service preparation and delivery, quarantines, cancellations, and disruptions to supply chains, workflow operations and consumer activity, as well as general concern and uncertainty. The impact of this coronavirus may be short-term or may last for an extended period of time and has resulted in a substantial economic downturn. Health crises caused by outbreaks, such as the coronavirus outbreak, may exacerbate other pre-existing political, social and economic risks. The impact of this outbreak, and other epidemics and pandemics that may arise in the future, could continue to negatively affect the worldwide economy, as well as the economies of individual countries, individual companies (including certain Fund service providers and issuers of the Fund's investments) and the markets in general in significant and unforeseen ways. Any such impact could adversely affect the Fund's performance.

# Report of Independent Registered Public Accounting Firm

# TO THE BOARD OF TRUSTEES OF FEDERATED HERMES INSURANCE SERIES AND SHAREHOLDERS OF FEDERATED HERMES KAUFMANN FUND II:

### **Opinion on the Financial Statements**

We have audited the accompanying statement of assets and liabilities, including the portfolio of investments, of Federated Hermes Kaufmann Fund II (formerly, Federated Kaufmann Fund II) (the "Fund"), a portfolio of Federated Hermes Insurance Series (formerly, Federated Insurance Series), as of December 31, 2020, the related statement of operations for the year then ended, the statements of changes in net assets for each of the years in the two year period then ended, and the related notes (collectively, the "financial statements") and the financial highlights for each of the years in the five year period then ended. In our opinion, the financial statements and financial highlights present fairly, in all material respects, the financial position of the Fund as of December 31, 2020, the results of its operations for the year then ended, the changes in its net assets for each of the years in the two year period then ended, and the financial highlights for each of the years in the five year period then ended, in conformity with U.S. generally accepted accounting principles.

### **Basis for Opinion**

These financial statements and financial highlights are the responsibility of the Fund's management. Our responsibility is to express an opinion on these financial statements and financial highlights based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Fund in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements and financial highlights are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements and financial highlights, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements and financial highlights. Such procedures also included confirmation of securities owned as of December 31, 2020, by correspondence with the custodian and brokers, or by other appropriate auditing procedures. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements and financial highlights. We believe that our audits provide a reasonable basis for our opinion.



We have served as the auditor of one or more of Federated Hermes' investment companies since 2006.

Boston, Massachusetts February 16, 2021

# Shareholder Expense Example (unaudited)

As a shareholder of the Fund, you incur ongoing costs, including management fees and to the extent applicable, distribution (12b-1) fees and/or other service fees and other Fund expenses. This Example is intended to help you to understand your ongoing costs (in dollars) of investing in the Fund and to compare these costs with the ongoing costs of investing in other funds used as variable investment options. It is based on an investment of \$1,000 invested at the beginning of the period and held for the entire period from July 1, 2020 to December 31, 2020.

### **ACTUAL EXPENSES**

The first section of the table below provides information about actual account values and actual expenses. You may use the information in this section, together with the amount you invested, to *estimate* the expenses that you incurred over the period. Simply divide your account value by \$1,000 (for example, an \$8,600 account value divided by \$1,000 = 8.6), then multiply the result by the number in the first section under the heading entitled "Expenses Paid During Period" to estimate the expenses attributable to your investment during this period.

### HYPOTHETICAL EXAMPLE FOR COMPARISON PURPOSES

The second section of the table below provides information about hypothetical account values and hypothetical expenses based on the Fund's actual expense ratio and an *assumed* rate of return of 5% per year before expenses, which is not the Fund's actual return. Thus, you should *not* use the hypothetical account values and expenses to estimate the actual ending account balance or your expenses for the period. Rather, these figures are required to be provided to enable you to compare the ongoing costs of investing in the Fund with other funds. To do so, compare this 5% hypothetical example with the 5% hypothetical examples that appear in the shareholder reports of the other funds.

Please note that the expenses shown in the table are meant to highlight your ongoing costs only. Therefore, the second section of the table is useful in comparing ongoing costs only, and will not help you determine the relative *total* costs of owning different funds.

	Beginning Account Value 7/1/2020	Ending Account Value 12/31/2020	Expenses Paid During Period
Actual:			
Primary Shares	\$1,000	\$1,162.60	\$8.15
Service Shares	\$1,000	\$1,161.60	\$9.45
Hypothetical (assuming a 5% return before expenses):			
Primary Shares	\$1,000	\$1,017.60	\$7.61
Service Shares	\$1,000	\$1,016.39	\$8.82

<sup>1</sup> Expenses are equal to the Fund's annualized net expense ratios, multiplied by the average account value over the period, multiplied by 184/366 (to reflect the one-half-year period). The expenses shown in the table do not include the charges and expenses imposed by the insurance company under the variable insurance product contract. Please refer to the variable insurance product prospectus for a complete listing of these expenses. The annualized net expense ratios are as follows:

Primary Shares 1.50% Service Shares 1.74%

# Board of Trustees and Trust Officers

The Board of Trustees is responsible for managing the Trust's business affairs and for exercising all the Trust's powers except those reserved for the shareholders. The following tables give information about each Trustee and the senior officers of the Fund. Where required, the tables separately list Trustees who are "interested persons" of the Fund (i.e., "Interested" Trustees) and those who are not (i.e., "Independent" Trustees). Unless otherwise noted, the address of each person listed is 1001 Liberty Avenue, Pittsburgh, PA 15222-3779. The address of all Independent Trustees listed is 4000 Ericsson Drive, Warrendale, PA 15086-7561; Attention: Mutual Fund Board. As of December 31, 2020, the Trust comprised six portfolio(s), and the Federated Hermes Fund Family consisted of 41 investment companies (comprising 163 portfolios). Unless otherwise noted, each Officer is elected annually. Unless otherwise noted, each Trustee oversees all portfolios in the Federated Hermes Fund Family and serves for an indefinite term. The Fund's Statement of Additional Information includes additional information about Trust Trustees and is available, without charge and upon request, by calling 1-800-341-7400.

### INTERESTED TRUSTEES BACKGROUND

Name Birth Date Positions Held with Trust Date Service Began	Principal Occupation(s) for Past Five Years, Other Directorships Held and Previous Position(s)	
J. Christopher Donahue* Birth Date: April 11, 1949 TRUSTEE Indefinite Term Began serving: September 1993		
	<b>Previous Positions</b> : President, Federated Investment Counseling; President and Chief Executive Officer, Federated Investment Management Company, Federated Global Investment Management Corp. and Passport Research, Ltd; Chairman, Passport Research, Ltd.	
Thomas R. Donahue* Birth Date: October 20, 1958 TRUSTEE Indefinite Term Began serving: May 2016	Principal Occupations: Director or Trustee of certain of the funds in the Federated Hermes Fund Family; Chief Financial Officer, Treasurer, Vice President and Assistant Secretary, Federated Hermes, Inc.; Chairman and Trustee, Federated Administrative Services; Chairman and Director, Federated Administrative Services, Inc.; Trustee and Treasurer, Federated Advisory Services Company; Director or Trustee and Treasurer, Federated Equity Management Company of Pennsylvania, Federated Global Investment Management Corp., Federated Investment Counseling, and Federated Investment Management Company; Director, MDTA LLC; Director, Executive Vice President and Assistant Secretary, Federated Securities Corp.; Director or Trustee and Chairman, Federated Services Company and Federated Shareholder Services Company; and Director and President, FII Holdings, Inc.	
	<b>Previous Positions</b> : Director, Federated Hermes, Inc.; Assistant Secretary, Federated Investment Management Company, Federated Global Investment Management Company and Passport Research, LTD; Treasurer, Passport Research, LTD; Executive Vice President, Federated Securities Corp.; and Treasurer, FII Holdings, Inc.	

<sup>\*</sup> Family relationships and reasons for "interested" status: J. Christopher Donahue and Thomas R. Donahue are brothers. Both are "interested" due to their beneficial ownership of shares of Federated Hermes, Inc. and the positions they hold with Federated Hermes, Inc. and its subsidiaries.

### INDEPENDENT TRUSTEES BACKGROUND

Name Birth Date Positions Held with Trust Date Service Began	Principal Occupation(s) for Past Five Years, Other Directorships Held, Previous Position(s) and Qualifications
John T. Collins Birth Date: January 24, 1947 TRUSTEE	<b>Principal Occupations</b> : Director or Trustee, and Chair of the Board of Directors or Trustees, of the Federated Hermes Fund Family; formerly, Chairman and CEO, The Collins Group, Inc. (a private equity firm) (Retired).
Indefinite Term Began serving: October 2013	<b>Other Directorships Held</b> : Chairman of the Board of Directors, Director, KLX Energy Services Holdings, Inc. (oilfield services); former Director of KLX Corp. (aerospace).
C. C	Qualifications: Mr. Collins has served in several business and financial management roles and directorship positions throughout his career. Mr. Collins previously served as Chairman and CEO of The Collins Group, Inc. (a private equity firm) and as a Director of KLX Corp. Mr. Collins serves as Chairman Emeriti, Bentley University. Mr. Collins previously served as Director and Audit Committee Member, Bank of America Corp.; Director, FleetBoston Financial Corp.; and Director, Beth Israel Deaconess Medical Center (Harvard University Affiliate Hospital).

Name **Birth Date Positions Held with Trust Date Service Began** 

Principal Occupation(s) for Past Five Years, Other Directorships Held, Previous Position(s) and Qualifications

G. Thomas Hough Birth Date: February 28, 1955 TRUSTEE

Principal Occupations: Director or Trustee, Chair of the Audit Committee of the Federated Hermes Fund Family; formerly, Vice Chair, Ernst & Young LLP (public accounting firm) (Retired).

Indefinite Term Began serving: August 2015

Other Directorships Held: Director, Chair of the Audit Committee, Equifax, Inc.; Director, Member of the Audit Committee, Haverty Furniture Companies, Inc.; formerly, Director, Member of Governance and Compensation Committees, Publix Super Markets, Inc.

Qualifications: Mr. Hough has served in accounting, business management and directorship positions throughout his career. Mr. Hough most recently held the position of Americas Vice Chair of Assurance with Ernst & Young LLP (public accounting firm). Mr. Hough serves on the President's Cabinet and Business School Board of Visitors for the University of Alabama. Mr. Hough previously served on the Business School Board of Visitors for Wake Forest University, and he previously served as an Executive Committee member of the United States Golf Association.

Maureen Lally-Green Birth Date: July 5, 1949 **TRUSTEE** Indefinite Term Began serving: August 2009 Principal Occupations: Director or Trustee of the Federated Hermes Fund Family; Adjunct Professor Emerita of Law, Duquesne University School of Law; formerly, Dean of the Duquesne University School of Law and Professor of Law and Interim Dean of the Duquesne University School of Law; formerly, Associate General Secretary and Director, Office of Church Relations, Diocese of Pittsburgh.

Other Directorships Held: Director, CNX Resources Corporation (formerly known as CONSOL Energy Inc.).

Qualifications: Judge Lally-Green has served in various legal and business roles and directorship positions throughout her career. Judge Lally-Green previously held the position of Dean of the School of Law of Duquesne University (as well as Interim Dean). Judge Lally-Green previously served as a member of the Superior Court of Pennsylvania and as a Professor of Law, Duquesne University School of Law. Judge Lally-Green was appointed by the Supreme Court of Pennsylvania to serve on the Supreme Court's Board of Continuing Judicial Education and the Supreme Court's Appellate Court Procedural Rules Committee. Judge Lally-Green also currently holds the positions on not for profit or for profit boards of directors as follows: Director and Chair, UPMC Mercy Hospital; Regent, Saint Vincent Seminary; Member, Pennsylvania State Board of Education (public); Director, Catholic Charities, Pittsburgh; and Director CNX Resources Corporation (formerly known as CONSOL Energy Inc.). Judge Lally-Green has held the positions of: Director, Auberle; Director, Epilepsy Foundation of Western and Central Pennsylvania; Director, Ireland Institute of Pittsburgh; Director, Saint Thomas More Society; Director and Chair, Catholic High Schools of the Diocese of Pittsburgh, Inc.; Director, Pennsylvania Bar Institute; Director, St. Vincent College; Director and Chair, North Catholic High School, Inc.; and Director and Vice Chair, Our Campaign for the Church Alive!, Inc.

Thomas M. O'Neill Birth Date: June 14, 1951 **TRUSTEE** Indefinite Term Began serving: August 2006 Principal Occupations: Director or Trustee of the Federated Hermes Fund Family; Sole Proprietor, Navigator Management Company (investment and strategic consulting).

Other Directorships Held: None.

Qualifications: Mr. O'Neill has served in several business, mutual fund and financial management roles and directorship positions throughout his career. Mr. O'Neill serves as Director, Medicines for Humanity and Director, The Golisano Children's Museum of Naples, Florida. Mr. O'Neill previously served as Chief Executive Officer and President, Managing Director and Chief Investment Officer, Fleet Investment Advisors; President and Chief Executive Officer, Aeltus Investment Management, Inc.; General Partner, Hellman, Jordan Management Co., Boston, MA; Chief Investment Officer, The Putnam Companies, Boston, MA; Credit Analyst and Lending Officer, Fleet Bank; Director and Consultant, EZE Castle Software (investment order management software); and Director, Midway Pacific (lumber).

Madelyn A. Reilly Birth Date: February 2, 1956 TRUSTEE Indefinite Term Began serving: November 2020

Principal Occupations: Director or Trustee of the Federated Hermes Fund Family; Senior Vice President for Legal Affairs, General Counsel and Secretary of the Board of Trustees, Duquesne University.

Other Directorships Held: None.

Qualifications: Ms. Reilly has served in various business and legal management roles throughout her career. Ms. Reilly previously served as Director of Risk Management and Associate General Counsel, Duquesne University. Prior to her work at Duquesné University, Ms. Reilly served as Assistant General Counsel of Compliance and Enterprise Risk as well as Senior Counsel of Environment, Health and Safety, PPG Industries.

P. Jerome Richey Birth Date: February 23, 1949 **TRUSTEE** Indefinite Term Began serving: October 2013

Principal Occupations: Director or Trustee of the Federated Hermes Fund Family; Management Consultant; Retired; formerly, Senior Vice Chancellor and Chief Legal Officer, University of Pittsburgh and Executive Vice President and Chief Legal Officer, CONSOL Energy Inc. (now split into two separate publicly traded companies known as CONSOL Energy Inc. and CNX Resources Corp.).

Other Directorships Held: None.

Qualifications: Mr. Richey has served in several business and legal management roles and directorship positions throughout his career. Mr. Richey most recently held the positions of Senior Vice Chancellor and Chief Legal Officer, University of Pittsburgh. Mr. Richey previously served as Chairman of the Board, Epilepsy Foundation of Western Pennsylvania and Chairman of the Board, World Affairs Council of Pittsburgh. Mr. Richey previously served as Chief Legal Officer and Executive Vice President, CONSOL Energy Inc. and CNX Gas Company; and Board Member, Ethics Counsel and Shareholder, Buchanan Ingersoll & Rooney PC (a law firm).

### Name Birth Date Positions Held with Trust Date Service Began

Principal Occupation(s) for Past Five Years,
Other Directorships Held, Previous Position(s) and Qualifications

John S. Walsh Birth Date: November 28, 1957 TRUSTEE Indefinite Term Began serving: January 1999 **Principal Occupations**: Director or Trustee of the Federated Hermes Fund Family; President and Director, Heat Wagon, Inc. (manufacturer of construction temporary heaters); President and Director, Manufacturers Products, Inc. (distributor of portable construction heaters); President, Portable Heater Parts, a division of Manufacturers Products, Inc.

Other Directorships Held: None.

**Qualifications**: Mr. Walsh has served in several business management roles and directorship positions throughout his career. Mr. Walsh previously served as Vice President, Walsh & Kelly, Inc. (paving contractors).

### **OFFICERS**

### Name Birth Date Address Positions Held with Trust Date Service Began

# Principal Occupation(s) for Past Five Years and Previous Position(s)

### Lori A. Hensler Birth Date: January 6, 1967 TREASURER Officer since: April 2013

**Principal Occupations**: Principal Financial Officer and Treasurer of the Federated Hermes Fund Family; Senior Vice President, Federated Administrative Services; Financial and Operations Principal for Federated Securities Corp.; and Assistant Treasurer, Federated Investors Trust Company. Ms. Hensler has received the Certified Public Accountant designation.

Previous Positions: Controller of Federated Hermes, Inc.; Senior Vice President and Assistant Treasurer, Federated Investors Management Company; Treasurer, Federated Investors Trust Company; Assistant Treasurer, Federated Administrative Services, Federated Administrative Services, Inc., Federated Securities Corp., Edgewood Services, Inc., Federated Advisory Services Company, Federated Equity Management Company of Pennsylvania, Federated Global Investment Management Corp., Federated Investment Management Company, Passport Research, Ltd., and Federated MDTA, LLC; Financial and Operations Principal for Federated Securities Corp., Edgewood Services, Inc. and Southpointe Distribution Services, Inc.

### Peter J. Germain Birth Date: September 3, 1959 CHIEF LEGAL OFFICER, SECRETARY AND EXECUTIVE VICE PRESIDENT Officer since: January 2005

Principal Occupations: Mr. Germain is Chief Legal Officer, Secretary and Executive Vice President of the Federated Hermes Fund Family. He is General Counsel, Chief Legal Officer, Secretary and Executive Vice President, Federated Hermes, Inc.; Trustee and Senior Vice President, Federated Investors Management Company; Trustee and President, Federated Administrative Services; Director and President, Federated Administrative Services, Inc.; Director and Vice President, Federated Securities Corp.; Director and Secretary, Federated Private Asset Management, Inc.; Secretary, Federated Shareholder Services Company; and Secretary, Retirement Plan Service Company of America. Mr. Germain joined Federated Hermes, Inc. in 1984 and is a member of the Pennsylvania Bar Association.

**Previous Positions**: Deputy General Counsel, Special Counsel, Managing Director of Mutual Fund Services, Federated Hermes, Inc.; Senior Vice President, Federated Services Company; and Senior Corporate Counsel, Federated Hermes, Inc.

### John B. Fisher Birth Date: May 16, 1956 PRESIDENT Officer since: November 2004

Principal Occupations: Principal Executive Officer and President of certain of the Funds in the Federated Hermes Fund Family; Director or Trustee of certain of the Funds in the Federated Hermes Fund Family; Vice President, Federated Hermes, Inc.; President, Director/Trustee and CEO, Federated Advisory Services Company, Federated Equity Management Company of Pennsylvania, Federated Global Investment Management Corp., Federated Investment Counseling, Federated Investment Management Company; President and CEO of Passport Research, Ltd.; President of some of the Funds in the Federated Fund Complex and Director, Federated Investors Trust Company.

**Previous Positions**: President and Director of the Institutional Sales Division of Federated Securities Corp.; President and Director of Federated Investment Counseling; Director, Edgewood Securities Corp.; Director, Federated Services Company; Director, Federated Hermes, Inc.; Chairman and Director, Southpointe Distribution Services, Inc. and President, Technology, Federated Services Company.

### Stephen Van Meter Birth Date: June 5, 1975 CHIEF COMPLIANCE OFFICER AND SENIOR VICE PRESIDENT Officer since: July 2015

**Principal Occupations**: Senior Vice President and Chief Compliance Officer of the Federated Hermes Fund Family; Vice President and Chief Compliance Officer of Federated Hermes, Inc. and Chief Compliance Officer of certain of its subsidiaries. Mr. Van Meter joined Federated Hermes, Inc. in October 2011. He holds FINRA licenses under Series 3, 7, 24 and 66.

**Previous Positions**: Mr. Van Meter previously held the position of Compliance Operating Officer, Federated Hermes, Inc. Prior to joining Federated Hermes, Inc., Mr. Van Meter served at the United States Securities and Exchange Commission in the positions of Senior Counsel, Office of Chief Counsel, Division of Investment Management and Senior Counsel, Division of Enforcement.

# Stephen F. Auth Birth Date: September 13, 1956 101 Park Avenue 41st Floor New York, NY 10178 CHIEF INVESTMENT OFFICER Officer since: November 2002

**Principal Occupations**: Stephen F. Auth is Chief Investment Officer of various Funds in the Federated Hermes Fund Family; Executive Vice President, Federated Investment Counseling, Federated Global Investment Management Corp. and Federated Equity Management Company of Pennsylvania.

**Previous Positions**: Executive Vice President, Federated Investment Management Company and Passport Research, Ltd. (investment advisory subsidiary of Federated); Senior Vice President, Global Portfolio Management Services Division; Senior Vice President, Federated Investment Management Company and Passport Research, Ltd.; Senior Managing Director and Portfolio Manager, Prudential Investments.

Name Birth Date Address Positions Held with Trust Date Service Began	Principal Occupation(s) for Past Five Years and Previous Position(s)
Robert J. Ostrowski Birth Date: April 26, 1963 CHIEF INVESTMENT OFFICER Officer since: May 2004	Principal Occupations: Robert J. Ostrowski joined Federated Hermes, Inc. in 1987 as an Investment Analyst and became a Portfolio Manager in 1990. He was named Chief Investment Officer of Federated Hermes' taxable fixed-income products in 2004 and also serves as a Senior Portfolio Manager. Mr. Ostrowski became an Executive Vice President of the Fund's Adviser in 2009 and served as a Senior Vice President of the Fund's Adviser from 1997 to 2009. Mr. Ostrowski has received the Chartered Financial Analyst designation. He received his M.S. in Industrial Administration from Carnegie Mellon University.
Deborah A. Cunningham Birth Date: September 15, 1959 CHIEF INVESTMENT OFFICER Officer since: June 2012	<b>Principal Occupations</b> : Deborah A. Cunningham was named Chief Investment Officer of Federated Hermes' money market products in 2004. She joined Federated Hermes in 1981 and has been a Senior Portfolio Manager since 1997 and an Executive Vice President of the Fund's Adviser since 2009. Ms. Cunningham has received the Chartered Financial Analyst designation and holds an M.S.B.A. in Finance from Robert Morris College.

# Evaluation and Approval of Advisory Contract – May 2020

### FEDERATED HERMES KAUFMANN FUND II (THE "FUND")

### (FORMERLY, FEDERATED KAUFMANN FUND II)

At its meetings in May 2020 (the "May Meetings"), the Fund's Board of Trustees (the "Board"), including a majority of those Trustees who are not "interested persons" of the Fund, as defined in the Investment Company Act of 1940 (the "Independent Trustees"), reviewed and unanimously approved the continuation of the investment advisory contract between the Fund and Federated Equity Management Company of Pennsylvania (the "Adviser") and the investment subadvisory contract between the Adviser and Federated Global Investment Management Corp. with respect to the Fund (together, the "Contracts") for an additional one-year term. The Board's determination to approve the continuation of the Contracts reflects the exercise of its business judgment after considering all of the information and factors believed to be relevant and appropriate on whether to continue the existing arrangements. The information, factors and conclusions that formed the basis for the Board's approval are summarized below.

### Information Received and Review Process

At the request of the Independent Trustees, the Fund's Chief Compliance Officer (the "CCO") furnished to the Board in advance of its May Meetings an independent written evaluation presenting on the topics discussed below. The Board considered the CCO's independent written evaluation (the "CCO Fee Evaluation Report"), along with other information, in evaluating the reasonableness of the Fund's management fee and in determining to approve the continuation of the Contracts. The CCO, in preparing the CCO Fee Evaluation Report, has the authority to retain consultants, experts or staff as reasonably necessary to assist in the performance of his duties, reports directly to the Board, and can be terminated only with the approval of a majority of the Independent Trustees. At the request of the Independent Trustees, the CCO Fee Evaluation Report followed the same general approach and covered the same topics as that of the report that had previously been delivered by the CCO in his capacity as "Senior Officer" prior to the elimination of the Senior Officer position in December 2017.

In addition to the extensive materials that comprise and accompany the CCO Fee Evaluation Report, in the months preceding the May Meetings, the Board requested and reviewed written responses and supporting materials prepared by the Adviser and its affiliates (collectively, "Federated Hermes") in response to requests posed to Federated Hermes on behalf of the Independent Trustees encompassing a wide variety of topics. The Board also considered such additional matters as the Independent Trustees deemed reasonably necessary to evaluate the Contracts, which included detailed information about the Fund and Federated Hermes furnished to the Board at its meetings throughout the year and in between regularly scheduled meetings on particular matters as the need arose, as well as information specifically prepared in connection with the approval of the continuation of the Contracts that was presented at the May Meetings.

The Board's consideration of the Contracts included review of materials and information covering the following matters, among others: the Adviser's and sub-adviser's investment philosophy, revenue, profitability, personnel and processes; investment and operating strategies; the Fund's short-term and long-term performance (in absolute terms, both on a gross basis and net of expenses, and relative to the Fund's particular investment program and a group of its peer funds and/or its benchmark, as appropriate) and comments on the reasons for the Fund's performance; the Fund's investment objectives; the Fund's expenses, including the advisory fee and the overall expense structure of the Fund (both in absolute terms and relative to a group of its peer funds), with due regard for contractual or voluntary expense limitations (if any); the use and allocation of brokerage commissions derived from trading the Fund's portfolio securities (if any); and the nature, quality and extent of the advisory and other services provided to the Fund by the Adviser and its affiliates. The Board also considered the preferences and expectations of Fund shareholders; the entrepreneurial and other risks assumed by the Adviser in sponsoring and managing the Fund; the continuing state of competition in the mutual fund industry and market practices; the range of comparable fees for similar funds in the mutual fund industry; the Fund's relationship to the other funds advised by Federated Hermes (each, a "Federated Hermes Fund"), which include a comprehensive array of funds with different investment objectives, policies and strategies which are generally available for exchange without the incurrence of additional sales charges; compliance and audit reports concerning the Federated Hermes Funds and the Federated Hermes' affiliates that service them (including communications from regulatory agencies), as well as Federated Hermes' responses to any issues raised therein; and relevant developments in the mutual fund industry and how the Federated Hermes Funds and/or Federated Hermes may be responding to them. In addition, the Board received and considered information furnished by Federated Hermes on the impacts of the coronavirus (COVID-19) outbreak on Federated Hermes generally and the Fund in particular, including, among other information, the current and anticipated impacts on the management, operations and performance of the Fund. The Board noted that its evaluation process is evolutionary and that the criteria considered and the emphasis placed on relevant criteria may change in recognition of changing circumstances in the mutual fund marketplace.

The Board also considered judicial decisions concerning allegedly excessive investment advisory fees in determining to approve the Contracts. Using these judicial decisions as a guide, the Board observed that the following factors may be relevant to an adviser's fiduciary duty with respect to its receipt of compensation from a fund: (1) the nature and quality of the services provided by an adviser to a fund and its shareholders (including the performance of the fund, its benchmark, and comparable funds); (2) an adviser's cost of providing the services (including the profitability to an adviser of providing advisory services to a fund); (3) the extent to which an adviser may realize "economies of scale" as a fund grows larger and, if such economies of scale exist, whether they have been shared with a fund and its shareholders or the family of funds; (4) any "fall-out" financial benefits that accrue to an adviser because of its relationship with a fund (including research services received from brokers that execute fund trades and any fees paid to affiliates of an adviser for services rendered to a fund); (5) comparative fee and expense structures (including a comparison of fees paid to an adviser with those paid by similar funds both internally and externally as well as management fees charged to institutional and other advisory clients of the adviser for what might be viewed as like services); and (6) the extent of care, conscientiousness and independence with which the fund's board members perform their duties and their expertise (including whether they are fully informed about all facts the board deems relevant to its consideration of an adviser's services and fees). The Board noted that the Securities and Exchange Commission ("SEC") disclosure requirements regarding the basis for a fund board's approval of the fund's investment advisory contracts generally align with the factors listed above. The Board was aware of these factors and was guided by them in its review of the Contracts to the extent it considered them to be appropriate and relevant, as discussed further below.

The Board considered and weighed these factors in light of its substantial accumulated experience in governing the Fund and working with Federated Hermes on matters relating to the Federated Hermes Funds. While individual members of the Board may have weighed certain factors differently, the Board's determination to continue the Contracts was based on a comprehensive consideration of all information provided to the Board throughout the year and specifically with respect to the continuation of the Contracts. The Independent Trustees were assisted throughout the evaluation process by independent legal counsel. In connection with their deliberations at the May Meetings, the Independent Trustees met separately in executive session with their independent legal counsel and without management present to review the relevant materials and consider their responsibilities under applicable laws. In addition, senior management representatives of Federated Hermes also met with the Independent Trustees and their independent legal counsel to discuss the materials and presentations furnished to the Board at the May Meetings. The Board considered the approval of the Contracts for the Fund as part of its consideration of agreements for funds across the Federated Hermes Funds family, but its approvals were made on a fund-by-fund basis.

### Nature, Extent and Quality of Services

The Board considered the nature, extent and quality of the services provided to the Fund by the Adviser and the resources of the Adviser and its affiliates dedicated to the Fund. In this regard, the Board evaluated, among other things, the Adviser's personnel, experience and track record, as well as the financial resources and overall reputation of Federated Hermes and its willingness to invest in personnel and infrastructure that benefit the Federated Hermes Funds. The Board noted the significant acquisition of Hermes Fund Managers Limited by Federated Hermes in 2018, which has deepened the organization's investment management expertise and capabilities and expanded the investment process for all of the Federated Hermes Funds to incorporate environmental, social and governance ("ESG") factors and issuer engagement on ESG matters.

In addition, the Board reviewed the qualifications, backgrounds and responsibilities of the portfolio management team primarily responsible for the day-to-day management of the Fund and the Adviser's ability and experience in attracting and retaining qualified personnel to service the Fund. The Board noted the compliance program of the Adviser and the compliance-related resources devoted by the Adviser and its affiliates in support of the Fund's obligations pursuant to Rule 38a-1 under the Investment Company Act of 1940, including the Adviser's commitment to respond to rulemaking and other regulatory initiatives of the SEC such as the liquidity risk management program rules. In addition, the Board considered the response by the Adviser to recent market conditions and considered the overall performance of the Adviser in this context. The Fund's ability to deliver competitive performance when compared to its Performance Peer Group (as defined below) was also deemed to be relevant by the Board as a useful indicator of how the Adviser is executing the Fund's investment program. The Adviser's ability to execute this program was one of the Board's considerations in reaching a conclusion that the nature, extent and quality of the Adviser's investment management and related services warrant the continuation of the Contracts.

### **Fund Investment Performance**

In evaluating the Fund's investment performance, the Board considered performance results in light of the Fund's investment objective, strategies and risks, as disclosed in the Fund's prospectus. The Board also considered the Fund's performance in light of the overall recent market conditions. The Board considered detailed investment reports on the Fund's performance over different time periods that were provided to the Board throughout the year and in connection

with the May Meetings and evaluated the Adviser's analysis of the Fund's performance for these time periods. The Board also reviewed comparative information regarding the performance of other mutual funds in the category of peer funds selected by Morningstar, Inc. (the "Morningstar"), an independent fund ranking organization (the "Performance Peer Group"), noting the CCO's view that comparisons to fund peer groups may be helpful, though not conclusive, in evaluating the performance of the Adviser in managing the Fund. The Board considered, in evaluating such comparisons, that in some cases there may be differences in the funds' objectives or investment management techniques, or the costs to implement the funds, even within the same Performance Peer Group. In this connection, the Board considered that the longevity and experience of the Fund's portfolio management team and their extensive bottom-up approach to investing may limit the utility of comparisons to other equity mutual funds.

For the one-year, three-year and five-year periods ended December 31, 2019, the Fund's performance was above the median of the relevant Performance Peer Group.

Following such evaluation, and full deliberations, the Board concluded that the performance of the Fund supported renewal of the Contracts.

### **Fund Expenses**

While mindful that courts have cautioned against giving too much weight to comparative information concerning fees charged by other advisers for managing funds with comparable investment programs, the Board has found the use of such comparisons to be relevant to its deliberations. In this regard, the Board was presented with, and considered, information regarding the contractual advisory fee rates, total expense ratios and each element of the Fund's total expense ratio (i.e., gross and net advisory fees, administrative fees, custody fees, portfolio accounting fees and transfer agency fees) relative to an appropriate group of peer funds compiled by Federated Hermes from the category of peer funds selected by Morningstar (the "Expense Peer Group"). The Board received a description of the methodology used to select the Expense Peer Group from the overall Morningstar category. The Board also reviewed comparative information regarding the fees and expenses of the broader group of funds in the overall Morningstar category. The Board focused on comparisons with other similar mutual funds more heavily than non-mutual fund products or services because such comparisons are believed to be more relevant. The Board considered that other mutual funds are the products most like the Fund, in that they are readily available to Fund shareholders as alternative investment vehicles, and they are the type of investment vehicle, in fact, chosen and maintained by the Fund's investors. The Board noted that the range of their fees and expenses, therefore, appears to be a relevant indicator of what consumers have found to be reasonable in the marketplace in which the Fund competes.

The Board reviewed the contractual advisory fee rate, and other expenses of the Fund and noted the position of the Fund's contractual advisory fee rate and other expenses relative to its Expense Peer Group. In this regard, the Board noted that the contractual advisory fee rate was above the median of the relevant Expense Peer Group, but the Board noted the applicable waivers and reimbursements, and that the overall expense structure of the Fund remained competitive in the context of other factors considered by the Board.

For comparison, the Board received and considered information about the fees charged by Federated Hermes for providing advisory services to other types of clients with investment strategies similar to those of the Federated Hermes Funds, including non-mutual fund clients such as institutional separate accounts and third-party unaffiliated mutual funds for which the Adviser or its affiliates serve as sub-adviser. The Board noted the CCO's conclusion that non-mutual fund clients are inherently different products due to the following differences, among others: (i) different types of targeted investors; (ii) different applicable laws and regulations; (iii) different legal structures; (iv) different average account sizes and portfolio management techniques made necessary by different cash flows and different associated costs; (v) and the time spent by portfolio managers and their teams (among other personnel across various departments, including legal, compliance and risk management) in reviewing securities pricing, addressing different administrative responsibilities, and addressing different degrees of risk associated with management; and (vi) a variety of different costs. The Board also considered information regarding the differences in the nature of the services required for Federated Hermes to manage its proprietary mutual fund business versus managing a discrete pool of assets as a sub-adviser to another institution's mutual fund, noting that Federated Hermes generally performs significant additional services and assumes substantially greater risks in managing the Fund and other Federated Hermes Funds than in its role as sub-adviser to an unaffiliated third-party mutual fund. The Board noted that the CCO did not consider the fees for providing advisory services to other types of clients to be determinative in judging the appropriateness of the Federated Hermes Funds' advisory fees.

Following such evaluation, and full deliberations, the Board concluded that the fees and expenses of the Fund are reasonable and supported renewal of the Contracts.

### **Profitability and Other Benefits**

The Board also received financial information about Federated Hermes, including information regarding the compensation and ancillary (or "fall-out") benefits Federated Hermes derived from its relationships with the Federated Hermes Funds. This information covered not only the fees under the Federated Hermes Funds' investment advisory contracts, but also fees received by Federated Hermes' affiliates for providing other services to the Federated Hermes Funds under separate contracts (e.g., for serving as the Federated Hermes Funds' administrator and distributor). In this regard, the Board considered that certain of Federated Hermes' affiliates provide distribution and shareholder services to the Federated Hermes Funds, for which they may be compensated through distribution and servicing fees paid pursuant to Rule 12b-1 plans or otherwise. The Board also received and considered information detailing any indirect benefit Federated Hermes may derive from its receipt of research services from brokers who execute portfolio trades for the Federated Hermes Funds. In addition, the Board considered the fact that, in order for the Federated Hermes Funds to be competitive in the marketplace, the Adviser and its affiliates frequently waived fees and/or reimbursed expenses and have disclosed to Federated Hermes Fund shareholders and/or reported to the Board their intention to do so in the future. Moreover, the Board received and considered regular reports from Federated Hermes throughout the year as to the institution, adjustment or elimination of these voluntary waivers and/or reimbursements. The Board considered Federated Hermes' previous reductions in contractual management fees to certain Federated Hermes Funds during the prior year, including in response to the CCO's recommendations in the prior year's CCO Fee Evaluation Report.

The Board received and considered information furnished by Federated Hermes, as requested by the CCO, that reported revenues on a fund-by-fund basis and made estimates of the allocation of expenses on a fund-by-fund basis, using allocation methodologies specified by the CCO and described to the Board. The Board considered the CCO's view that, while these cost allocation reports apply consistent allocation processes, the inherent difficulties in allocating costs continues to cause the CCO to question the precision of the process and to conclude that such reports may be unreliable, because a single change in an allocation estimate may dramatically alter the resulting estimate of cost and/or profitability of a Federated Hermes Fund and may produce unintended consequences. The allocation information, including the CCO's view that fund-by-fund estimations may be unreliable, was considered in the evaluation by the Board. In addition, the Board considered that, during the prior year, an independent consultant conducted a review of the allocation methodologies used by Federated Hermes in estimating profitability for purposes of reporting to the Board in connection with the continuation of the Contracts. The Board noted the consultant's view that, although there is no single best method to allocate expenses, the methodologies used by Federated Hermes are reasonable.

The Board also reviewed information compiled by Federated Hermes comparing its profitability information to other publicly held fund management companies, including information regarding profitability trends over time. The Board considered the CCO's conclusion that, based on such profitability information, Federated Hermes' profit margins did not appear to be excessive. The Board also considered the CCO's view that Federated Hermes appeared financially sound, with the resources necessary to fulfill its obligations under its contracts with the Federated Hermes Funds.

### **Economies of Scale**

The Board received and considered information about the notion of possible realization of "economies of scale" as a fund grows larger, the difficulties of calculating economies of scale at an individual fund level, and the extent to which potential scale benefits are shared with shareholders. In this regard, the Board considered that the Adviser has made significant and long-term investments in areas that support all of the Federated Hermes Funds, such as personnel and processes for the portfolio management, trading operations, issuer engagement (including with respect to ESG matters), shareholder services, compliance, business continuity, internal audit and risk management functions, as well as systems technology (including technology relating to cybersecurity) and use of data. The Board noted that Federated Hermes' investments in these areas are extensive and are designed to provide enhanced services to the Federated Hermes Funds and their shareholders. The Board considered that the benefits of these investments (as well as the benefits of any economies of scale, should they exist) are likely to be shared with the Federated Hermes Fund family as a whole. In addition, the Board considered that the Adviser and its affiliates have frequently waived fees and/or reimbursed expenses for the Federated Hermes Funds and that such waivers and reimbursements are another means for potential economies of scale to be shared with shareholders and can provide protection from an increase in expenses if a Federated Hermes Fund's assets decline. Federated Hermes, as it does throughout the year, and specifically in connection with the Board's review of the Contracts, furnished information relative to adviser-paid fees (commonly referred to as revenue sharing). The Board considered the beliefs of Federated Hermes and the CCO that this information should be viewed to determine if there was an incentive to either not apply breakpoints, or to apply breakpoints at higher levels, and should not be viewed to determine the appropriateness of advisory fees. The Board also noted the absence of any applicable regulatory or industry guidelines on this subject, which is compounded by the lack of any common industry practice or general pattern with respect to structuring fund advisory fees with "breakpoints" that serve to reduce the fee as a fund attains a certain size.

### **Conclusions**

The Board considered the CCO's conclusion that his observations and the information accompanying the CCO Fee Evaluation Report show that the management fee for the Fund was reasonable and the CCO's recommendation that the Board approve the management fee. The Board noted that, under these circumstances, no changes were recommended to, and no objection was raised to the continuation of, the Contracts by the CCO. The CCO also recognized that the Board's evaluation of the Federated Hermes Funds' advisory and subadvisory arrangements is a continuing and on-going process that is informed by the information that the Board requests and receives from management throughout the course of the year and, in this regard, the CCO noted certain items for future reporting to the Board or further consideration by management as the Board continues its on-going oversight of the Federated Hermes Funds.

In its determination to continue an existing investment advisory contract, the Board was mindful of the potential disruptions of the Fund's operations and various risks, uncertainties and other effects that could occur as a result of a decision to terminate or not renew an investment advisory contract. In particular, the Board recognized that many shareholders have invested in the Fund on the strength of the Adviser's industry standing and reputation and with the expectation that the Adviser will have a continuing role in providing advisory services to the Fund. Thus, the Board's approval of the Contracts reflected the fact that it is the shareholders who have effectively selected the Adviser by virtue of having invested in the Fund. The Board concluded that, in light of the factors summarized above, including the nature, quality and scope of the services provided to the Fund by the Adviser and its affiliates, continuation of the Contracts was appropriate.

The Board based its determination to approve the Contracts on the totality of the circumstances and relevant factors and with a view to past and future long-term considerations. Not all of the factors and considerations identified above were necessarily deemed to be relevant to the Fund, nor did the Board consider any one of them to be determinative. With respect to the factors that were deemed to be relevant, the Board's determination to approve the continuation of the Contracts reflects its view that Federated Hermes' performance and actions provided a satisfactory basis to support the determination to continue the existing arrangements.

# Liquidity Risk Management Program – Annual Evaluation of Adequacy and Effectiveness

In accordance with Rule 22e-4 under the Investment Company Act of 1940, as amended (the "Liquidity Rule"), Federated Hermes Insurance Series (the "Trust") has adopted and implemented a liquidity risk management program (the "Program") for Federated Hermes Kaufmann Fund II (the "Fund" and, collectively with the Federated Hermes funds, the "Federated Hermes Funds"). The Program seeks to assess and manage the Fund's liquidity risk. "Liquidity risk" is defined under the Liquidity Rule as the risk that the Fund is unable to meet redemption requests without significantly diluting remaining investors' interests in the Fund. The Board of Trustees of the Trust (the "Board") has approved the designation of the Fund's investment adviser as the administrator for the Program for the Fund. Each affiliated Federated Hermes advisory subsidiary (including the Fund's investment adviser) that serves as investment adviser to a Federated Hermes Fund (including the Fund) has been approved as the administrator of the Program for each Federated Hermes Fund they manage (each an "Administrator"). The Administrator in turn has delegated daily responsibility for the administration of the Program to multiple Liquidity Risk Management Committees (the "Committees"). The Committees, which are comprised of representatives of Enterprise Risk Management, Compliance, Investment Management and Trading, must review and assess certain information related to the liquidity of the Federated Hermes Funds, including the Fund.

The Program is comprised of various components designed to support the assessment and/or management of liquidity risk, including: (1) the periodic assessment (no less frequently than annually) of certain factors that influence the Fund's liquidity risk; (2) the periodic classification (no less frequently than monthly) of the Fund's investments into one of four liquidity categories that reflect an estimate of their liquidity under current market conditions; (3) a 15% limit on the acquisition of "illiquid investments" (as defined under the Liquidity Rule); (4) to the extent a Fund does not invest primarily in "highly liquid investments" (as defined under the Liquidity Rule), the determination of a minimum percentage of the Fund's assets that generally will be invested in highly liquid investments (an "HLIM"); (5) if a Fund has established an HLIM, the periodic review (no less frequently than annually) of the HLIM and the adoption of policies and procedures for responding to a shortfall of the Fund's highly liquid investments below its HLIM; and (6) periodic reporting to the Board.

At its meetings in May 2020, the Board received and reviewed a written report (the "Report") from the Federated Hermes Funds' Chief Compliance Officer and Chief Risk Officer, on behalf of the Administrator, concerning the operation of the Program for the period from the Program's inception on December 1, 2018 through March 31, 2020 (the "Period"). The Report addressed the operation of the Program and assessed its adequacy and effectiveness, including, where applicable, the operation of any HLIM established for a Federated Hermes Fund and each Federated Hermes Fund's access to other available funding sources such as the Federated Hermes Funds' interfund lending facility, redemptions in-kind and committed lines of credit. There were no material changes to the Program during the Period. The Report summarized the operation of the Program and the information and factors considered by the Administrator in assessing whether the Program has been adequately and effectively implemented with respect to the Federated Hermes Funds. Such information and factors included, among other things:

- confirmation that the Fund did not utilize alternative funding sources during the Period;
- the periodic classifications of the Fund's investments into one of four liquidity categories and the methodologies and inputs used to classify the investments, including the Fund's reasonably anticipated trade size;
- the analysis received from a third-party liquidity assessment vendor that is taken into account in the process of determining the liquidity classifications of the Fund's investments and the results of an evaluation of the services performed by the vendor in support of this process;
- the fact that the Fund invested primarily in highly liquid investments during the Period and, therefore, was not required to establish, and has not established, an HLIM and the procedures for monitoring the status of the Fund as investing primarily in highly liquid investments;
- the fact that the Fund invested no more than 15% of its assets in illiquid investments during the Period and the procedures for monitoring this limit; and
- liquidity events during the Period, including the impact on liquidity caused by extended non-U.S. market closures and the market disruptions resulting from the novel coronavirus outbreak, and the fact that there were no specific liquidity events during the Period that materially affected the Fund's liquidity risk.

Based on this review, the Fund's investment adviser, in its role as Administrator, collectively with the other investment advisers to the Federated Hermes Funds, concluded that the Program is operating effectively to assess and manage the Fund's liquidity risk, and that the Program has been and continues to be adequately and effectively implemented to monitor and, as applicable, respond to the Fund's liquidity developments.

# Voting Proxies on Fund Portfolio Securities

A description of the policies and procedures that the Fund uses to determine how to vote proxies, if any, relating to securities held in the Fund's portfolio is available, without charge and upon request, by calling 1-800-341-7400. A report on "Form N-PX" of how the Fund voted any such proxies during the most recent 12-month period ended June 30 is available via the Proxy Voting Record (Form N-PX) link associated with the Fund and share class name at FederatedInvestors.com/FundInformation. Form N-PX filings are also available at the SEC's website at sec.gov.

# Quarterly Portfolio Schedule

Each fiscal quarter, the Fund will file with the SEC a complete schedule of its monthly portfolio holdings on "Form N-PORT." The Fund's holdings as of the end of the third month of every fiscal quarter, as reported on Form N-PORT, will be publicly available on the SEC's website at <a href="sec.gov">sec.gov</a> within 60 days of the end of the fiscal quarter upon filing. You may also access this information via the link to the Fund and share class name at <a href="FederatedInvestors.com">FederatedInvestors.com</a>.

Notes

Notes

Notes

Variable investment options are not bank deposits or obligations, are not guaranteed by any bank and are not insured or guaranteed by the U.S. government, the Federal Deposit Insurance Corporation, the Federal Reserve Board or any other government agency. Investment in variable investment options involves investment risk, including the possible loss of principal.

This Report is authorized for distribution to prospective investors only when preceded or accompanied by the Fund's Prospectus, which contains facts concerning its objective and policies, management fees, expenses and other information.



Federated Hermes Kaufmann Fund II Federated Hermes Funds 4000 Ericsson Drive Warrendale, PA 15086-7561

Contact us at <u>FederatedInvestors.com</u> or call 1-800-341-7400.

Federated Securities Corp., Distributor

CUSIP 313916827 CUSIP 313916777

28136 (2/21)

© 2021 Federated Hermes, Inc.